[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 61504
1. Oguzkurt P, Ince E, Temiz A, Demir S, Akabolat F, Hicsonmez A: Prenatal diagnosis of a mass in the adrenal region that proved to be a teratoma. J Pediatr Hematol Oncol; 2009 May;31(5):350-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prenatal diagnosis of a mass in the adrenal region that proved to be a teratoma.
  • Magnetic resonance imaging showed a 57 x 50 mm mass in the left adrenal region displacing the kidney inferiorly.
  • The infant underwent an adrenalectomy with total resection of the tumor, which proved on histologic examination to be a mature teratoma.
  • Prenatally detected suprarenal masses are likely to be neuroblastoma or adrenal hemorrhage, but may be rare benign lesions such as extralobar pulmonary sequestration, bronchogenic cyst, or renal dysplasia.
  • Although teratoma in the adrenal region is extremely rare, it should be included in the clinical and radiologic differential diagnosis of prenatally detected suprarenal masses.
  • Total excision of the mass for histologic diagnosis is indicated.
  • [MeSH-major] Adrenal Gland Neoplasms / congenital. Adrenal Gland Neoplasms / diagnosis. Teratoma / congenital. Teratoma / diagnosis. Ultrasonography, Prenatal
  • [MeSH-minor] Adrenalectomy. Biopsy. Diagnosis, Differential. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Pregnancy

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415017.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Verrey F, Singer D, Ramadan T, Vuille-dit-Bille RN, Mariotta L, Camargo SM: Kidney amino acid transport. Pflugers Arch; 2009 May;458(1):53-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney amino acid transport.
  • Near complete reabsorption of filtered amino acids is a main specialized transport function of the kidney proximal tubule.
  • A number of other amino acid transporters expressed in the basolateral membrane of proximal kidney tubule cells subserve either specialized metabolic functions, such as the production of ammonium, or are part of the cellular housekeeping equipment.
  • Some mutations of B(0)AT1 differentially interact with these accessory subunits, providing an explanation for differential intestinal phenotypes among Hartnup patients.
  • The basolateral efflux of numerous amino acids from kidney tubular cells is mediated by heteromeric amino acid transporters that function as obligatory exchangers.
  • [MeSH-major] Amino Acid Transport Systems / metabolism. Amino Acids / metabolism. Kidney / metabolism
  • [MeSH-minor] Amino Acid Transport Systems, Neutral / metabolism. Amino Acid Transport Systems, Neutral / physiology. Animals. Anion Transport Proteins / physiology. Antiporters / physiology. Biological Transport. Humans. Kidney Tubules, Proximal / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1999 Mar;21(3):293-6 [10080182.001]
  • [Cites] Nature. 1996 Oct 17;383(6601):634-7 [8857541.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Aug;310(2):695-702 [15051798.001]
  • [Cites] Pflugers Arch. 2005 Nov;451(2):338-48 [16133263.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2000 Jan;3(1):51-7 [10642084.001]
  • [Cites] Gene. 2002 Jun 12;292(1-2):81-90 [12119102.001]
  • [Cites] J Biol Chem. 1999 Dec 3;274(49):34948-54 [10574970.001]
  • [Cites] Am J Clin Nutr. 2004 Feb;79(2):185-97 [14749222.001]
  • [Cites] Pflugers Arch. 2003 Feb;445(5):529-33 [12634921.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):999-1002 [15286787.001]
  • [Cites] J Am Soc Nephrol. 2003 Apr;14(4):837-47 [12660317.001]
  • [Cites] Physiol Rev. 1998 Oct;78(4):969-1054 [9790568.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):21017-26 [11907033.001]
  • [Cites] Physiol Rev. 2008 Jan;88(1):249-86 [18195088.001]
  • [Cites] J Clin Invest. 2008 Dec;118(12):3881-92 [19033659.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1088-91 [17167413.001]
  • [Cites] EMBO J. 1999 Jan 4;18(1):49-57 [9878049.001]
  • [Cites] Biochem J. 2005 Aug 1;389(Pt 3):745-51 [15804236.001]
  • [Cites] Nature. 2004 Oct 14;431(7010):811-8 [15483603.001]
  • [Cites] Pflugers Arch. 2004 Feb;447(5):465-8 [14624363.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):14883-90 [8662767.001]
  • [Cites] Tohoku J Exp Med. 2006 Jan;208(1):25-31 [16340170.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 16;304(4):747-54 [12727219.001]
  • [Cites] Nature. 1992 Dec 3;360(6403):467-71 [1280334.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1410-22 [15521011.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Feb;292(2):F555-66 [17003226.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Feb;290(2):F376-83 [16174864.001]
  • [Cites] J Biol Chem. 1998 Dec 4;273(49):32437-45 [9829974.001]
  • [Cites] Pflugers Arch. 2004 Feb;447(5):610-8 [12905028.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):24467-76 [15044460.001]
  • [Cites] J Inherit Metab Dis. 2007 Oct;30(5):716-21 [17588131.001]
  • [Cites] Am J Physiol. 1997 Dec;273(6 Pt 2):F1023-9 [9435692.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Feb;292(2):F533-44 [16985211.001]
  • [Cites] Annu Rev Nutr. 1995;15:133-59 [8527215.001]
  • [Cites] FASEB J. 2008 Aug;22(8):2880-7 [18424768.001]
  • [Cites] Pflugers Arch. 2004 Feb;447(5):776-9 [12748860.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2002 Feb;282(2):E428-34 [11788376.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10 ):4166-73 [15121838.001]
  • [Cites] Biochem J. 2005 Mar 15;386(Pt 3):417-22 [15689184.001]
  • [Cites] Nature. 2005 Sep 8;437(7056):215-23 [16041361.001]
  • [Cites] J Membr Biol. 2001 Apr 1;180(3):213-20 [11337893.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7206-11 [11390972.001]
  • [Cites] J Membr Biol. 1999 Dec 1;172(3):181-92 [10568788.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Sep;281(3):C963-71 [11502573.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Jan;280(1):F10-8 [11133510.001]
  • [Cites] J Membr Biol. 1982;66(3):213-25 [6808139.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):8974-84 [15632147.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):872-82 [19185582.001]
  • [Cites] Pflugers Arch. 2007 Jun;454(3):507-16 [17273864.001]
  • [Cites] Curr Probl Clin Biochem. 1976;6:173-89 [11964.001]
  • [Cites] Physiology (Bethesda). 2006 Apr;21:93-102 [16565475.001]
  • [Cites] J Cell Physiol. 2006 Mar;206(3):771-9 [16245314.001]
  • [Cites] Annu Rev Physiol. 2005;67:557-72 [15709970.001]
  • [Cites] Physiol Rev. 1990 Jan;70(1):43-77 [2404290.001]
  • [Cites] J Biol Chem. 2003 Jan 10;278(2):1316-22 [12417581.001]
  • [Cites] Nat Genet. 1999 Mar;21(3):297-301 [10080183.001]
  • [Cites] J Am Soc Nephrol. 2005 Apr;16(4):869-77 [15716335.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 May;284(5):F885-92 [12676733.001]
  • [Cites] J Biol Chem. 2006 Sep 8;281(36):26552-61 [16825196.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):1003-7 [15286788.001]
  • (PMID = 19184091.001).
  • [ISSN] 1432-2013
  • [Journal-full-title] Pflugers Archiv : European journal of physiology
  • [ISO-abbreviation] Pflugers Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Amino Acid Transport Systems; 0 / Amino Acid Transport Systems, Neutral; 0 / Amino Acids; 0 / Anion Transport Proteins; 0 / Antiporters; 0 / SLC26A8 protein, human; 0 / SLC6A19 protein, human
  • [Number-of-references] 60
  •  go-up   go-down


3. Zhou Y, Vaidya VS, Brown RP, Zhang J, Rosenzweig BA, Thompson KL, Miller TJ, Bonventre JV, Goering PL: Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol Sci; 2008 Jan;101(1):159-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium.
  • Sensitive biomarkers are needed to detect kidney injury at the earliest stages.
  • The objective of this study was to determine whether the appearance of kidney injury molecule-1 (Kim-1) protein ectodomain in urine and kidney injury molecule-1/hepatitis A viral cellular receptor-1 (Kim-1/Havcr1) gene expression in kidney tissue may be more predictive of renal injury after exposure to nephrotoxicants when compared to traditionally used biomarkers.
  • The results showed that increases in urinary Kim-1 and kidney Kim-1/Havcr1 gene expression paralleled the degree of severity of renal histopathology and were detected at lower doses of nephrotoxicants when compared to blood urea nitrogen (BUN), serum creatinine, and urinary N-acetyl-beta-D-glucosaminidase (NAG).
  • Urinary Kim-1 and kidney Kim-1/Havcr1 expression appear to be sensitive and tissue-specific biomarkers that will improve detection of early acute kidney injury following exposure to nephrotoxic chemicals and drugs.

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Mercury.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MERCURY, ELEMENTAL .
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Vitaminol Enzymol. 1984;6(2):103-7 [6496253.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Jan;292(1):F313-20 [16896183.001]
  • [Cites] Environ Health Perspect. 1991 May;92:71-4 [1935854.001]
  • [Cites] Pharmacol Toxicol. 1991 May;68(5):317-21 [1946176.001]
  • [Cites] Gen Pharmacol. 1995 Nov;26(7):1477-87 [8690234.001]
  • [Cites] EMBO J. 1996 Aug 15;15(16):4282-96 [8861957.001]
  • [Cites] Drug Saf. 1997 Mar;16(3):205-31 [9098657.001]
  • [Cites] J Biol Chem. 1998 Feb 13;273(7):4135-42 [9461608.001]
  • [Cites] Toxicol Pathol. 1998 Jan-Feb;26(1):92-103 [9502391.001]
  • [Cites] J Virol. 1998 Aug;72(8):6621-8 [9658108.001]
  • [Cites] J Am Soc Nephrol. 2005 Apr;16(4):1126-34 [15744000.001]
  • [Cites] BMC Nephrol. 2005;6:4 [15854231.001]
  • [Cites] J Am Soc Nephrol. 2005 Nov;16(11):3365-70 [16177006.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Feb;290(2):F517-29 [16174863.001]
  • [Cites] J Am Soc Nephrol. 2007 Mar;18(3):904-12 [17267747.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):371-81 [17325478.001]
  • [Cites] Ren Fail. 2002 Nov;24(6):687-90 [12472192.001]
  • [Cites] Free Radic Biol Med. 2003 Jun 1;34(11):1390-8 [12757849.001]
  • [Cites] Toxicol Sci. 2003 Sep;75(1):208-22 [12832660.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Mar;286(3):F552-63 [14600030.001]
  • [Cites] Am J Med. 1968 May;44(5):664-705 [5646427.001]
  • [Cites] Toxicol Appl Pharmacol. 1980 Jul;54(3):443-53 [6446781.001]
  • [Cites] J Toxicol Environ Health. 1982 Jan;9(1):119-26 [6460873.001]
  • [Cites] Biochem Pharmacol. 1982 Oct 1;31(19):3093-100 [6216890.001]
  • [Cites] Pharmacol Rev. 2000 Mar;52(1):113-43 [10699157.001]
  • [Cites] Therapie. 2000 Jan-Feb;55(1):91-6 [10860006.001]
  • [Cites] J Environ Sci Health B. 2001 Sep;36(5):687-97 [11599730.001]
  • [Cites] Kidney Int. 2002 Jul;62(1):237-44 [12081583.001]
  • [Cites] Cleve Clin J Med. 2002 Jul;69(7):569-74 [12109642.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39739-48 [12138159.001]
  • [Cites] Kidney Int. 1991 Apr;39(4):639-46 [1711136.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Aug;291(2):F456-64 [16467126.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Jan;292(1):F131-9 [16835406.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Dec;283(6):F1326-36 [12388382.001]
  • (PMID = 17934191.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK 072831; United States / NIEHS NIH HHS / ES / ES016723-02; United States / NIDDK NIH HHS / DK / R37 DK039773; United States / NIDDK NIH HHS / DK / DK 074099; United States / NIDDK NIH HHS / DK / R01 DK072381-04; United States / NIDDK NIH HHS / DK / R01 DK072381; United States / NIDDK NIH HHS / DK / R33 DK074099; United States / NIEHS NIH HHS / ES / R00 ES016723-02; United States / NIDDK NIH HHS / DK / DK 039773; United States / NIDDK NIH HHS / DK / R21 DK074099; United States / NIEHS NIH HHS / ES / R00 ES016723; United States / NIDDK NIH HHS / DK / R01 DK039773; None / None / / R01 DK072381-04
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cell Adhesion Molecules; 0 / Gentamicins; 0 / Havcr1protein, rat; 0 / Membrane Proteins; 0 / Protein Synthesis Inhibitors; 0R0008Q3JB / Chromium; 63231-63-0 / RNA; 7535-00-4 / Galactosamine; FXS1BY2PGL / Mercury; V956696549 / Acetylglucosamine
  • [Other-IDs] NLM/ NIHMS110357; NLM/ PMC2744478
  •  go-up   go-down


Advertisement
4. Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT: MicroRNA profiling of human kidney cancer subtypes. Int J Oncol; 2009 Jul;35(1):109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA profiling of human kidney cancer subtypes.
  • In order to understand their role in renal tumorigenesis, we screened the expression levels of miRNAs in four subtypes of human renal neoplasms: clear cell, papillary, and chromophobe renal cell carcinomas (RCC) as well as benign renal oncocytomas.
  • We found a unique miRNA signature for each subtype of renal tumor.
  • Specifically, we documented the overexpression of miRs 424 and 203 in clear cell RCC relative to papillary RCC, as well as the inversion of expression of miR-203 in the benign oncocytomas (where it is underexpressed relative to normal kidney) as compared to the malignant chromophobe RCC (where it is overexpressed relative to normal kidney).
  • While previous studies have identified unique miRNA expression pattern distinguishing tumors from different anatomical locations, here we extend this principle to demonstrate the utility of miRNA expression profiling to identify a signature unique to various tumor subtypes at a single anatomic locus.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Gene Expression Profiling / methods. Kidney Neoplasms / genetics. MicroRNAs / analysis

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19513557.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


5. Boorjian SA, Frank I, Inman B, Lohse CM, Cheville JC, Leibovich BC, Blute ML: The role of partial nephrectomy for the management of sporadic renal angiomyolipoma. Urology; 2007 Dec;70(6):1064-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of partial nephrectomy for the management of sporadic renal angiomyolipoma.
  • OBJECTIVES: Angiomyolipoma is a benign renal tumor that has a propensity to grow over time and may cause local complications.
  • Given the benign nature of these lesions, renal-preserving treatments are favored.
  • We evaluated our experience with nephron-sparing surgery for renal angiomyolipoma.
  • METHODS: We reviewed our institutional nephrectomy registry to identify patients treated with nephron-sparing surgery for renal angiomyolipoma between 1970 and 2004.
  • Patients with a diagnosis of tuberous sclerosis were excluded.
  • RESULTS: We identified 58 patients treated with nephron-sparing surgery for sporadic renal angiomyolipoma, including 44 women and 14 men.
  • The median tumor size was 3.9 cm (range, 0.8-12.5 cm).
  • No patient developed de novo chronic renal insufficiency after nephron-sparing surgery, including 4 patients treated for angiomyolipomas in a solitary kidney.
  • CONCLUSIONS: Nephron-sparing surgery for sporadic renal angiomyolipomas offers preservation of renal function and is associated with acceptable complication and low local recurrence rates.
  • [MeSH-major] Angiomyolipoma / surgery. Kidney Neoplasms / surgery. Nephrectomy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158015.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Resende L, Guerra J, Santana A, Mil-Homens C, Abreu F, da Costa AG: Influence of dialysis duration and modality on kidney transplant outcomes. Transplant Proc; 2009 Apr;41(3):837-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of dialysis duration and modality on kidney transplant outcomes.
  • BACKGROUND: The influence of pretransplantation dialysis on kidney transplant outcomes has been the subject of longstanding interest.
  • Although increased time on dialysis prior to kidney transplantation is associated with decreased graft and patient survivals, analyses of the impact of dialysis modality on kidney allograft outcome have produced conflicting results.
  • OBJECTIVE: The objective of this study was to evaluate the influence of dialysis duration and modality on the function and survival of renal allografts.
  • PATIENTS: We retrospectively reviewed the clinical data of 421 adults who received first kidney transplantations from cadaveric heart-beating donors performed in our unit from May 1989 to May 2007.
  • Three hundred seventy-four patients (88.8%) were on hemodialysis (HD) prior to kidney transplantation, including 247 patients (58.7%) on treatment for at least 24 months.
  • Renal function at 3, 12, 60, and 96 months was similar between the 2 groups.
  • No differences were observed in renal function or graft and patient survivals comparing HD or peritoneal dialysis (PD).
  • [MeSH-major] Kidney Failure, Chronic / surgery. Kidney Transplantation / physiology. Renal Dialysis
  • [MeSH-minor] Adult. Age Factors. Female. Graft Survival. Humans. Kidney Function Tests. Living Donors. Male. Middle Aged. Postoperative Complications / epidemiology. Retrospective Studies. Sex Characteristics. Survival Analysis. Survivors. Time Factors. Tissue Donors / supply & distribution. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19376365.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Casas-Aparicio G, Castillo-Martínez L, Orea-Tejeda A, Abasta-Jiménez M, Keirns-Davies C, Rebollar-González V: The effect of successful kidney transplantation on ventricular dysfunction and pulmonary hypertension. Transplant Proc; 2010 Nov;42(9):3524-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of successful kidney transplantation on ventricular dysfunction and pulmonary hypertension.
  • BACKGROUND: Heart disease is a frequent complication of chronic kidney disease and the major cause of death in patients on renal replacement therapy.
  • The purpose of this study was to evaluate the impact of successful kidney transplantation on systolic and diastolic ventricular dysfunction and pulmonary arterial hypertension in patients with chronic kidney disease (CKD).
  • METHODS: The study included 35 patients >18 years of age with CKD who had successful kidney transplantations.
  • The LVEF of the entire group increased from 52% to 64% (P < .001) by 12 months after kidney transplant.
  • CONCLUSIONS: Because kidney transplantation led to considerable improvement in left ventricular systolic and diastolic function as well as pulmonary arterial pressure of patients with CKD, optimal treatment for dysfunction and transplant as soon as possible is recommended.
  • [MeSH-major] Hypertension, Pulmonary / etiology. Kidney Failure, Chronic / surgery. Kidney Transplantation. Ventricular Dysfunction, Left / etiology


8. Canales MT, Kasiske BL, Rosenberg ME: Transplant tourism: Outcomes of United States residents who undergo kidney transplantation overseas. Transplantation; 2006 Dec 27;82(12):1658-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplant tourism: Outcomes of United States residents who undergo kidney transplantation overseas.
  • BACKGROUND: Although international commerce in kidney transplantation is a reality, little is known about U.S. residents who travel abroad for kidney transplantation.
  • METHODS: We retrospectively reviewed the clinical outcomes of patients who were evaluated at the University of Minnesota Medical Center or Hennepin County Medical Center, but then surreptitiously underwent kidney transplantation overseas.
  • RESULTS: We identified 10 patients who underwent kidney transplantation outside the United States between September 16, 2002 and June 30, 2006 and then returned for care in our programs.
  • CONCLUSIONS: Kidney function and graft survival were generally good after surreptitious overseas kidney transplantation.
  • [MeSH-major] Graft Survival. Kidney Transplantation. Travel


9. Mosconi G, Panicali L, Persici E, Conte D, Cappuccilli ML, Cuna V, Capelli I, Todeschini P, D'Arcangelo GL, Stefoni S: Native kidney function after renal transplantation combined with other solid organs in preemptive patients. Transplant Proc; 2010 May;42(4):1017-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Native kidney function after renal transplantation combined with other solid organs in preemptive patients.
  • Kidney transplantations combined with other solid organs are progressively increasing in number.
  • There are no guidelines regarding the nephrologic indications for combined transplantations, namely liver-kidney (LKT), or heart-kidney (HKT), in preemptive patients with chronic kidney failure who are not on regular dialysis therapy.
  • The objective of this study was to assess the functional contribution of the native kidneys after preemptive kidney transplantation combined with other solid organs.
  • From 2004, 9 patients (aged 50.3 +/- 8.5 years) with chronic kidney failure (creatinine 2.5 +/- 1.0 mg/dL) caused by polycystic kidney disease (n = 4), vascular nephropathy (n = 2), interstitial nephropathy (n = 1), glomerulonephritis (n = 1), or end-stage kidney disease (n = 1), underwent combined transplantations (8 LKT, 1 HKT).
  • A scintigraphic functional study (Tc-99DMSA or Tc-99mMAG3), was performed at 4 +/- 3 months after transplantation to evaluate the functional contribution of both the native kidneys and the graft.
  • At the time of scintigraphy, renal function in all patients was 1.3 +/- 0.3 mg/dL.
  • The functional contribution of the transplanted kidneys was on average 77 +/- 18%.
  • At follow-up after 36 months, patient and kidney survivals were 100%.
  • The study confirmed a high risk of loss of native kidney function in the presence of organic nephropathy.
  • [MeSH-major] Kidney Transplantation / physiology. Organ Transplantation / physiology
  • [MeSH-minor] Adult. Creatinine / blood. Female. Glomerular Filtration Rate. Heart Transplantation / physiology. Humans. Kidney Diseases / classification. Kidney Diseases / surgery. Kidney Failure, Chronic / surgery. Kidney Function Tests. Liver Transplantation / physiology. Male. Middle Aged. Polycystic Kidney Diseases / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Inc.
  • (PMID = 20534213.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


10. Sundaram S, Tasker AD, Morrell NW: Familial spontaneous pneumothorax and lung cysts due to a Folliculin exon 10 mutation. Eur Respir J; 2009 Jun;33(6):1510-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1977, Birt, Hogg and Dube (BHD) described a genodermatosis characterised by benign tumours of the hair follicle that has been associated with renal neoplasms and spontaneous pneumothorax.
  • In addition, we report an antenatal diagnosis (34 weeks gestation) of lung cysts in one affected family member.
  • Genetic analysis in the family has revealed a unique deletion mutation (c. 1537 del-C) involving exon 10.
  • [MeSH-major] Cysts / genetics. Lung Diseases / genetics. Pneumothorax / genetics. Proto-Oncogene Proteins / genetics. Tumor Suppressor Proteins / genetics

  • Genetics Home Reference. consumer health - primary spontaneous pneumothorax.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483054.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / FLCN protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


11. Jiang JC, Li CG, Liang QQ, Bian Q, Zhou Q, Cui XJ, Huang M, Liu QG, Lu S, Zhou CJ, Shi Q, Wang YJ: [Establishment of a rat model of cervical syndrome with kidney deficiency]. Zhong Xi Yi Jie He Xue Bao; 2008 Oct;6(10):1034-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment of a rat model of cervical syndrome with kidney deficiency].
  • OBJECTIVE: To establish a rat model of cervical syndrome (CS) with kidney deficiency.
  • METHODS: A group of 30 three-month-old female Sprague-Dawley rats were randomly divided into normal control group, CS group and CS with kidney deficiency group (combined group), with 10 rats in each group.
  • Rats in the normal control group received no treatment, rats in the CS group underwent only resection of cervical muscles and ligaments as unbalanced dynamic and static animal model, and rats in combined group underwent resection of both cervical muscles and ovaries as kidney deficiency model.
  • Kidney deficiency was determined by observing the morphologic changes of uterus and appendages, detecting the weight of uterus and appendages and the content of serum estradiol (E(2)).
  • CONCLUSION: The rat model of CS with kidney deficiency is established.
  • Kidney deficiency can aggravate cervical intervertebral disc degeneration.
  • [MeSH-minor] Animals. Female. Kidney Diseases. Ovariectomy. Random Allocation. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18847538.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


12. El-Agroudy AE, Sabry AA, Wafa EW, Neamatalla AH, Ismail AM, Mohsen T, Khalil AA, Shokeir AA, Ghoneim MA: Long-term follow-up of living kidney donors: a longitudinal study. BJU Int; 2007 Dec;100(6):1351-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of living kidney donors: a longitudinal study.
  • OBJECTIVE: To analyse retrospectively the general health status and renal and cardiovascular consequences of living-related kidney donation, as the long-term effects of unilateral nephrectomy for kidney donation are of particular interest with the currently increasing practice of living-donor transplantation.
  • PATIENTS AND METHODS: Living-related kidney donors (1400) who had donated their kidneys between 1976 and 2002 were asked to attend a dedicated donor follow-up clinic starting in 2004.
  • We attempted to contact all donors to determine the long-term outcome of their remaining kidney.
  • All kidney donors who responded had a detailed assessment, and were questioned about rehabilitation and their feelings on donating a kidney.
  • [MeSH-major] Health Status. Kidney. Living Donors. Nephrectomy / adverse effects. Tissue and Organ Harvesting / adverse effects

  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17941927.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Kestenbaum B, Rudser KD, de Boer IH, Peralta CA, Fried LF, Shlipak MG, Palmas W, Stehman-Breen C, Siscovick DS: Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med; 2008 Apr 1;148(7):501-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis.
  • BACKGROUND: Kidney disease and hypertension commonly coexist, yet the direction of their association is still debated.
  • OBJECTIVE: To evaluate whether early kidney dysfunction, measured by serum cystatin C levels and urinary albumin excretion, predates hypertension in adults without clinically recognized kidney or cardiovascular disease.
  • PARTICIPANTS: 2767 MESA participants without prevalent hypertension, cardiovascular disease, or clinically recognized kidney disease (an estimated glomerular filtration rate <60 mL/min per 1.73 m2 or microalbuminuria).
  • LIMITATIONS: Unmeasured characteristics may have confounded observed associations of kidney markers with hypertension.
  • CONCLUSION: Differences in kidney function, indicated by cystatin C levels, are associated with incident hypertension among individuals without clinical kidney or cardiovascular disease.
  • These population-based findings complement experimental work implicating early kidney damage in the pathogenesis of essential hypertension.

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Kidney Dis. 1996 Dec;28(6):811-21 [8957032.001]
  • [Cites] J Hum Hypertens. 1996 Oct;10(10):691-4 [9004096.001]
  • [Cites] Diabetes Care. 1998 Jul;21(7):1076-9 [9653598.001]
  • [Cites] Ann Intern Med. 1999 Mar 16;130(6):461-70 [10075613.001]
  • [Cites] Scand J Clin Lab Invest. 1999 Feb;59(1):1-8 [10206092.001]
  • [Cites] Lancet. 1963 Mar 30;1(7283):677-82 [14014100.001]
  • [Cites] Circulation. 2005 Mar 22;111(11):1370-6 [15738353.001]
  • [Cites] Am J Transplant. 2001 Sep;1(3):222-7 [12102255.001]
  • [Cites] Lancet. 2002 Aug 31;360(9334):659-65 [12241871.001]
  • [Cites] Arch Intern Med. 2005 Apr 25;165(8):923-8 [15851645.001]
  • [Cites] Kidney Int. 2005 Jun;67(6):2089-100 [15882252.001]
  • [Cites] N Engl J Med. 2005 May 19;352(20):2049-60 [15901858.001]
  • [Cites] Kidney Int Suppl. 2005 Aug;(97):S68-77 [16014104.001]
  • [Cites] Mayo Clin Proc. 2005 Oct;80(10):1270-7 [16212138.001]
  • [Cites] J Am Soc Nephrol. 2006 Feb;17(2):331-5 [16434504.001]
  • [Cites] Ann Intern Med. 2006 Aug 15;145(4):247-54 [16908915.001]
  • [Cites] Am J Kidney Dis. 2000 Jul;36(1):29-34 [10873868.001]
  • [Cites] N Engl J Med. 2002 Mar 21;346(12):913-23 [11907292.001]
  • [Cites] J Am Soc Nephrol. 2002 Apr;13(4):1034-9 [11912263.001]
  • [Cites] Am J Epidemiol. 2002 Nov 1;156(9):871-81 [12397006.001]
  • [Cites] Am J Kidney Dis. 2003 Jan;41(1):1-12 [12500213.001]
  • [Cites] N Engl J Med. 2003 Jan 9;348(2):101-8 [12519920.001]
  • [Cites] Diabetes Care. 2003 Nov;26(11):3160-7 [14578255.001]
  • [Cites] Hypertension. 2003 Dec;42(6):1206-52 [14656957.001]
  • [Cites] Kidney Int. 2004 Apr;65(4):1416-21 [15086483.001]
  • [Cites] Am J Med. 1972 May;52(5):584-94 [4337474.001]
  • [Cites] Circ Res. 1975 Jun;36(6):692-6 [1093748.001]
  • [Cites] J Clin Invest. 1986 Jun;77(6):1993-2000 [3011863.001]
  • [Cites] Arch Intern Med. 1987 May;147(5):943-4 [3555378.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):683-92 [1607909.001]
  • [Cites] N Engl J Med. 1992 Jul 16;327(3):151-6 [1608406.001]
  • [Cites] Lancet. 1992 Dec 12;340(8833):1435-6 [1360561.001]
  • [Cites] BMJ. 1993 Jan 2;306(6869):24-7 [8435572.001]
  • [Cites] Hypertension. 1994 Sep;24(3):301-8 [8082936.001]
  • [Cites] Kidney Int. 1995 Jan;47(1):312-8 [7731163.001]
  • [Cites] Clin Exp Hypertens. 1996 Apr-May;18(3-4):305-21 [8743023.001]
  • [Cites] Circulation. 1996 Sep 15;94(6):1310-5 [8822985.001]
  • [CommentIn] Ann Intern Med. 2008 Aug 19;149(4):284; author reply 284 [18711167.001]
  • (PMID = 18378946.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HC / N01-HC-95162; United States / NHLBI NIH HHS / HC / N01-HC-95163; United States / NHLBI NIH HHS / HL / N01HC95169; United States / NHLBI NIH HHS / HC / N01-HC-95159; United States / NCRR NIH HHS / RR / KL2 RR025015-01; United States / NHLBI NIH HHS / HC / N01-HC-95165; United States / NCATS NIH HHS / TR / TL1 TR000422; United States / NHLBI NIH HHS / HC / N01-HC-95169; United States / NHLBI NIH HHS / HC / N01-HC-95164; United States / NHLBI NIH HHS / HL / N01HC95165; United States / NHLBI NIH HHS / HL / N01HC95159; United States / NHLBI NIH HHS / HC / N01-HC-95160; United States / NIDDK NIH HHS / DK / K23 DK63274-01; United States / NCRR NIH HHS / RR / KL2 RR025015; United States / NHLBI NIH HHS / HC / N01-HC-95161; United States / NCATS NIH HHS / TR / UL1 TR000423; United States / NIDDK NIH HHS / DK / K23 DK063274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CST3 protein, human; 0 / Cystatin C; 0 / Cystatins; AYI8EX34EU / Creatinine
  • [Other-IDs] NLM/ NIHMS267500; NLM/ PMC3044648
  •  go-up   go-down


14. Ranganathan N, Ranganathan P, Friedman EA, Joseph A, Delano B, Goldfarb DS, Tam P, Rao AV, Anteyi E, Musso CG: Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther; 2010 Sep;27(9):634-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease.
  • INTRODUCTION: Uremic syndrome consists of nitrogenous waste retention, deficiency in kidney-derived hormones, and reduced acid excretion, and, if untreated, may progress to coma and eventual death.
  • Previous experience suggests that oral administration of a probiotic formulation of selected microbial strains may extend renoprotection via intraintestinal extraction of toxic waste solutes in patients with chronic kidney disease (CKD)stages 3 and 4.
  • [MeSH-major] Probiotics. Renal Insufficiency, Chronic / therapy. Uremia / prevention & control
  • [MeSH-minor] Adult. Aged. Argentina. Canada. Creatinine / analysis. Dietary Supplements / standards. Disease Progression. Double-Blind Method. Female. Humans. Kidney Function Tests. Male. Middle Aged. Nigeria. Pilot Projects. Protective Agents / pharmacokinetics. Quality of Life. Self Report. Treatment Outcome. United States. Uric Acid / analysis. Young Adult

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Chronic Kidney Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20721651.001).
  • [ISSN] 1865-8652
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protective Agents; 268B43MJ25 / Uric Acid; AYI8EX34EU / Creatinine
  •  go-up   go-down


15. Veroux M, Corona D, Giuffrida G, Gagliano M, Vizcarra D, Tallarita T, Zerbo D, Giaquinta A, Sorbello M, Macarone M, Veroux P: Sirolimus-based immunosuppression in kidney transplantation for type 2 diabetic nephropathy. Urol Int; 2010;84(3):301-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sirolimus-based immunosuppression in kidney transplantation for type 2 diabetic nephropathy.
  • INTRODUCTION: Kidney transplantation is the best replacement therapy of type 2 diabetic patients and recently similar graft and patient survival between diabetic and nondiabetic recipients has been reported.
  • We present our experience with sirolimus-based immunosuppression in a population of 24 type 2 diabetic patients who underwent a kidney transplantation.
  • PATIENTS AND METHODS: From January 2001 to December 2006, 396 kidney transplantations were performed.
  • Twenty-four patients had type 2 diabetes mellitus as a cause of end-stage renal disease.
  • A slightly better kidney functionality was observed in group B patients.
  • CONCLUSIONS: Sirolimus-based immunosuppression is safe and efficacious in type 2 diabetic patients who underwent a kidney transplantation, allowing a better glucose metabolism control.
  • [MeSH-major] Diabetes Mellitus, Type 2 / complications. Diabetic Nephropathies / etiology. Diabetic Nephropathies / surgery. Immunosuppression. Immunosuppressive Agents / therapeutic use. Kidney Transplantation. Sirolimus / therapeutic use


16. Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, Al-Ahmadie H, Alves V, Xiao SY, Anders RA, Hart JA: Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol; 2010 Aug;34(8):1147-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms.
  • The distinction of hepatocellular carcinoma (HCC) from metastatic tumor in the liver often presents a diagnostic challenge that carries significant impact on prognostication and therapy.
  • The sensitivities of Arg-1 in well, moderately, and poorly differentiated HCCs are 100%, 96.2%, and 85.7%, respectively, whereas, in comparison, HepPar-1 demonstrated sensitivities of 100%, 83.0%, and 46.4% for well, moderately, and poorly differentiated tumors, respectively.
  • We also examined Arg-1 expression in nonhepatocellular tumors, including many that are potential mimics of HCC (renal cell carcinomas, neuroendocrine tumors, melanomas, gastric adenocarcinomas, and adrenocortical carcinomas) and found that only 2 non-HCC tumors were reactive for Arg-1.
  • Arg-1 represents a sensitive and specific marker of benign and malignant hepatocytes that may ultimately prove to be a useful diagnostic tool in routine surgical pathology practice.
  • [MeSH-major] Arginase / analysis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / enzymology. Hepatocytes / enzymology. Immunohistochemistry. Liver Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Clin Nutr Metab Care. 1998 Jul;1(4):335-9 [10565370.001]
  • [Cites] J Biomed Biotechnol. 2010;2010:683485 [20029630.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):689-94 [11345832.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):978-88 [12170084.001]
  • [Cites] Hum Pathol. 2002 Dec;33(12):1175-81 [12514785.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):361-6 [12645337.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7565-73 [15187136.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):884-92 [15198362.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):514-20 [15221469.001]
  • [Cites] J Nutr. 2004 Oct;134(10 Suppl):2820S-2825S; discussion 2853S [15465793.001]
  • [Cites] Histochemistry. 1987;87(5):465-70 [3323144.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1050-4 [7692729.001]
  • [Cites] Int J Dev Neurosci. 1994 Jun;12(4):337-42 [7976488.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):686-92 [9237179.001]
  • [Cites] J Immunol. 1998 Jun 1;160(11):5347-54 [9605134.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):934-8 [9796718.001]
  • [Cites] Histopathology. 1998 Oct;33(4):318-24 [9822920.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2549-56 [15546957.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Acta Cytol. 2006 May-Jun;50(3):257-62 [16780018.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Aug;28(4):181-7 [16927637.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):308-14 [16896894.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1570-5 [17122513.001]
  • [Cites] Arch Pathol Lab Med. 2007 Nov;131(11):1648-54 [17979482.001]
  • [Cites] Lab Invest. 2008 Jan;88(1):78-88 [18026163.001]
  • [Cites] Toxicology. 2008 Mar 20;245(3):194-205 [18291570.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):224-30 [18628091.001]
  • [Cites] Arch Pathol Lab Med. 2008 Nov;132(11):1723-8 [18976006.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Dec 12;377(2):337-40 [18831962.001]
  • [Cites] BMC Dev Biol. 2008;8:107 [19000307.001]
  • [Cites] Int J Oncol. 2009 Mar;34(3):649-56 [19212669.001]
  • [Cites] PLoS Pathog. 2009 Apr;5(4):e1000371 [19360123.001]
  • [Cites] Acta Biochim Pol. 2009;56(3):465-9 [19636440.001]
  • [Cites] J Pathol. 2009 Nov;219(3):365-72 [19718708.001]
  • [Cites] Nitric Oxide. 2009 Nov-Dec;21(3-4):175-83 [19638312.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):874-81 [10955454.001]
  • (PMID = 20661013.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK081417; United States / NIDDK NIH HHS / DK / R01 DK081417-01; United States / NIDDK NIH HHS / DK / R01 DK081417-02
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.3.1 / Arginase
  • [Other-IDs] NLM/ NIHMS316258; NLM/ PMC3160135
  •  go-up   go-down


17. Liu SK, Yan C, Wu LL, Pan Y: [Study strategies for neurobiology mechanism of "kidney storing will and responding to fear"]. Zhong Xi Yi Jie He Xue Bao; 2010 Feb;8(2):106-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study strategies for neurobiology mechanism of "kidney storing will and responding to fear"].
  • The theory of traditional Chinese medicine (TCM) deems that kidney essence is the material basis of formation, development and function of the brain and it maintains human being's psychomotility and behavior.
  • Moreover, kidney essence is the material basis of emotional activity.
  • The emotion theory in TCM deems that kidney stores will and responds to fear.
  • Combining the TCM theory with the modern psychological theory on stress, and from the points of views of the emotion regulation, the formation, consolidation, extraction and extinction of fear memory, and the plasticity of amygdala-hippocampus-prefrontal cortex nervous pathway, as well as the results of pharmacological studies of prescriptions and herbs for invigorating the kidney, the authors explained in this article the pathological mechanisms of kidney deficiency due to attack of fear, and revealed the material basis, the action modes, and the neurobiological mechanisms of the kidney in controlling and regulating emotional activity.
  • [MeSH-major] Fear / physiology. Kidney / physiology. Medicine, Chinese Traditional. Stress, Psychological

  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141730.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


18. El-Husseini TK, Egail SA, Al-Orf AM, Mostert C: Ossifying renal tumor of infancy. Saudi Med J; 2005 Dec;26(12):1978-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ossifying renal tumor of infancy.
  • Ossifying renal tumor of infancy ORTI is a benign neoplasm, which presents with gross hematuria and less frequently as an abdominal mass, histologically it comprises a large cell with an epithelial nature and osteoid formation.
  • We report a case of a 10-month-old girl who developed ORTI as non-opacified upper calyces of left kidney on excretory urography.
  • We outlined the calcific and tumors nature of the lesion by ultrasound and computed tomography.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Ossification, Heterotopic / pathology. Ossification, Heterotopic / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16380785.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


19. Temmar M, Liabeuf S, Renard C, Czernichow S, Esper NE, Shahapuni I, Presne C, Makdassi R, Andrejak M, Tribouilloy C, Galan P, Safar ME, Choukroun G, Massy Z: Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens; 2010 Jan;28(1):163-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulse wave velocity and vascular calcification at different stages of chronic kidney disease.
  • BACKGROUND: Increased arterial stiffness and vascular calcification have been recognized as important predictors of cardiovascular mortality in patients with chronic kidney disease.
  • METHOD: In order to examine the precise temporal link between aortic stiffness and cardiovascular risk at the earliest stages of chronic kidney disease, we studied a cohort of 150 patients with chronic kidney disease (52 stage 2/3 patients, 51 stage 4/5 patients and 47 stage 5D patients).
  • RESULTS: Regardless of the disease stage, patients with chronic kidney disease had higher adjusted pulse wave velocity than controls with preserved renal function (14.6 +/- 3.8 vs. 10.7 +/- 1.7 m/s, respectively; P < 0.0001).
  • Regarding aortic calcification, there was a gradual but significant rise in later chronic kidney disease stages.
  • CONCLUSION: We found that both vascular stiffness and vascular calcification appear early in patients with chronic kidney disease, but only vascular calcification worsens as the disease progresses.
  • The increase of vascular stiffness in adult patients with chronic kidney disease seems to be more related to age, systolic blood pressure, diabetes and vascular calcification than to uremic toxicity.
  • [MeSH-major] Aorta, Abdominal / pathology. Aorta, Thoracic / pathology. Blood Circulation / physiology. Blood Pressure / physiology. Calcinosis / pathology. Kidney Failure, Chronic / pathology

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927012.001).
  • [ISSN] 1473-5598
  • [Journal-full-title] Journal of hypertension
  • [ISO-abbreviation] J. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


20. Andratschke N, Schnaiter A, Weber WA, Cai L, Schill S, Wiedenmann N, Schwaiger M, Molls M, Nieder C: Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction. Int J Radiat Oncol Biol Phys; 2006 Apr 1;64(5):1513-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction.
  • PURPOSE: To test whether the clinically available growth factor erythropoietin (EPO) influences radiation-induced normal-tissue damage in a model of kidney dysfunction.
  • METHODS: Animal experiments were conducted to test the role of EPO administration in a C3H mouse model of unilateral kidney irradiation with 6, 8, and 10 Gy and to assess the effects of 2 different dose levels of EPO.
  • The kidney function was assessed before radiotherapy, as well as 19, 25, 31, and 37 weeks thereafter by means of (99m)Tc-dimercaptosuccinat scans (static scintigraphy).
  • RESULTS: Concomitant EPO administration significantly increased the degree of radiation-induced kidney dysfunction.
  • CONCLUSION: Administration of growth factors concomitant to radiotherapy might modify the development of kidney dysfunction.
  • Although insulin-like growth factor-1 has previously been shown to protect the kidney, such an effect could not be demonstrated for EPO.
  • [MeSH-major] Erythropoietin / adverse effects. Kidney / radiation effects. Radiation Injuries, Experimental / prevention & control. Radiation Tolerance / drug effects

  • Hazardous Substances Data Bank. EPOETIN ALFA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):960. Schnaitera, Andrea [corrected to Schnaiter, Andrea]; Caia, Lu [corrected to Cai, Lu]
  • (PMID = 16580501.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 494JNQ8L28 / Technetium Tc 99m Dimercaptosuccinic Acid; 64FS3BFH5W / Epoetin Alfa
  •  go-up   go-down


21. Feltes CM, Van Eyk J, Rabb H: Distant-organ changes after acute kidney injury. Nephron Physiol; 2008;109(4):p80-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distant-organ changes after acute kidney injury.
  • Acute kidney injury (AKI) contributes significantly to morbidity and mortality in both adults and children.
  • Leukocyte trafficking, cytokine expression, cell adhesion-molecule expression and membrane ion and water-channel expression in distant organs are deranged after kidney injury.
  • The responses to oxidative stress after AKI are also altered, suggesting complex mechanisms of crosstalk between the injured kidney and distant organs.
  • [MeSH-major] Acute Kidney Injury / complications. Acute Kidney Injury / immunology. Cytokines / immunology. Models, Immunological. Multiple Organ Failure / complications. Multiple Organ Failure / immunology. Neutrophil Activation / immunology


22. Cheng L, Williamson SR, Zhang S, Maclennan GT, Montironi R, Lopez-Beltran A: Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy. Expert Rev Anticancer Ther; 2010 Jun;10(6):843-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy.
  • Renal neoplasms exhibit a wide spectrum of molecular characteristics that are closely associated with their diverse morphologic manifestations and clinical behaviors.
  • A wealth of information has been garnered via methodology ranging from classical cytogenetics to FISH and gene expression profiling; however, the exact mechanisms by which each type of renal tumor develops remain incompletely understood.
  • Oddly, tumors with distinctly different morphology and prognosis sometimes show some overlap in the observed genetic abnormalities; by contrast, morphologically well characterized benign and malignant tumors that seem intuitively related cannot necessarily be shown to exhibit a step-wise progression from benign to malignant biologic behavior.
  • Nevertheless, modern methodologies have been highly successful, not only in subclassifying renal tumors, but also in defining previously unrecognized entities.
  • We review the molecular and genetic characteristics of renal neoplasms, with emphasis on markers that demonstrate utility in differentiating morphologically similar neoplasms and in predicting clinical outcome.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / therapy. Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20553210.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 209
  •  go-up   go-down


23. Alie TM, Vrljicak PJ, Myburgh DB, Gupta IR: Microinjection and electroporation of embryonic kidney explants: an improved method. Kidney Int; 2007 Jul;72(1):121-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microinjection and electroporation of embryonic kidney explants: an improved method.
  • Embryonic kidney explants are routinely used to study the molecular regulation of kidney development.
  • In this study, we show that a high voltage with a short pulse time is preferable for mouse kidney explants.
  • We suggest that our described conditions will make microinjection and electroporation a more effective method to study gene function in the developing mouse kidney.
  • [MeSH-major] Electroporation / methods. Kidney / embryology. Microinjections / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495853.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins; EC 3.2.1.23 / beta-Galactosidase
  •  go-up   go-down


24. Argani P: Metanephric neoplasms: the hyperdifferentiated, benign end of the Wilms tumor spectrum? Clin Lab Med; 2005 Jun;25(2):379-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metanephric neoplasms: the hyperdifferentiated, benign end of the Wilms tumor spectrum?
  • Metanephric neoplasms represent a spectrum of differentiated lesions that seem most likely to be related to Wilms tumor.
  • These neoplasms include a pure stromal lesion, a pure epithelial lesion (MA), and a mixed epithelial-stromal lesion (MAF).
  • The continuity of these lesions with Wilms tumor has been demonstrated best in the epithelial lesions.
  • The relationship of Wilms tumor, MAF with mitoses or combined MA/Wilms tumor lesions, and usual MAF or usual MA may be viewed as analogous to that of neuroblastoma, differentiating neuroblastoma, and ganglioneuroma, in which progressively more mature or differentiated counterparts of malignant embryonal lesions are associated with a greater probability of benign clinical behavior.
  • Such a spectrum already is recognized for cystic ILNR-derived nephroblastic lesions, ranging from cystic Wilms tumor, cystic partially differentiated nephroblastoma, and cystic nephroma.
  • Although this concept implies that the more active lesions (Wilms tumor) mature with time into inactive ones (usual MAFs or MA), the converse (that an active Wilms tumor can arise within an inactive usual MAF or MA) remains possible.
  • [MeSH-major] Kidney Neoplasms / pathology. Wilms Tumor / pathology
  • [MeSH-minor] Adenofibroma / pathology. Adenoma / pathology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / pathology. Diagnosis, Differential. Humans. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848742.001).
  • [ISSN] 0272-2712
  • [Journal-full-title] Clinics in laboratory medicine
  • [ISO-abbreviation] Clin. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


25. Yang XJ, Zhou M, Hes O, Shen S, Li R, Lopez J, Shah RB, Yang Y, Chuang ST, Lin F, Tretiakova MM, Kort EJ, Teh BT: Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization. Am J Surg Pathol; 2008 Feb;32(2):177-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization.
  • The nature of tubulocystic carcinoma, a rare renal tumor composed of tubular and cystic structures, is poorly understood.
  • It has been suggested that it may represent a low-grade collecting duct carcinoma of the kidney despite the lack of sufficient molecular and pathologic evidence.
  • The aim of this study was to examine the clinical and pathologic features of 13 cases of tubulocystic carcinoma of the kidney.
  • Furthermore, using gene expression microarray analysis, we defined the molecular signature of this tumor by comparing it with other renal tumors in our previously established molecular profile database.
  • Histologically, all 13 tumors were composed of closely packed tubules and cysts of varying sizes separated by fibrovascular septa.
  • The epithelial lining cells of the tubules and cysts in this tumor were characterized by abundant eosinophilic cytoplasm with prominent nucleoli often showing a hobnail appearance.
  • Five of the 13 cases coexisted with papillary renal cell carcinoma (RCC) (n=3) or papillary adenoma (n=2).
  • Therefore, based on its unique pathologic features and molecular signature as well as its biologic behavior to develop metastasis either by itself or in association with papillary RCC, tubulocystic carcinoma of the kidney should be recognized as a distinct subtype of RCC and be distinguished from other malignant and benign cystic lesions of the kidney.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Renal Cell / secondary. Chromosome Aberrations. Cystadenocarcinoma / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosomes, Human, Pair 17. Disease-Free Survival. Female. Fluorescent Antibody Technique, Indirect. Gene Expression Regulation, Neoplastic. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasms, Multiple Primary. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223319.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Costa MG, Garcia VD, Leirias MM, Santos SR, Oliveira DM: Urgency priority in kidney transplantation in Rio Grande do Sul. Transplant Proc; 2007 Mar;39(2):381-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urgency priority in kidney transplantation in Rio Grande do Sul.
  • In 2002, it was established a system of urgency priority for kidney transplantations in cases with no vascular or peritoneal access for dialysis.
  • We reviewed cases of urgency priority request for kidney transplantation addressed to the CNCDO from May 2002 to August 2005.
  • Within this period the CNCDO received 35 urgency priority requests for kidney transplantation (mean, 1 every 1.2 months).
  • Among the 31 accepted, 26 (83%) had the transplantation performed in an average time of 19.6 days (range, 1-90), representing only 3.2% of all cadaveric kidney transplantations during that period.
  • [MeSH-major] Kidney Transplantation / statistics & numerical data. Tissue and Organ Procurement / statistics & numerical data. Waiting Lists

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17362736.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Ahmadnia H, Shamsa A, Yarmohammadi A, Darabi M, Asl Zare M: Kidney transplantation in older adults: does age affect graft survival? Urol J; 2005;2(2):93-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney transplantation in older adults: does age affect graft survival?
  • INTRODUCTION: There is a paucity of data on long-term patient and graft survival in the older kidney recipients.
  • Our aim was to evaluate the long-term outcomes of kidney transplantation in patients aged 50 years and older and compare them with outcomes in younger recipients.
  • Patients who had received a cadaveric kidney allograft were excluded from the study.
  • CONCLUSION: Kidney transplantation should be considered in patients older than 50 years, since the graft survival rate is acceptable in this population, and early mortality and complications in this group are not different than those of younger recipients.
  • Although older patients have a shorter life expectancy, they benefit from renal transplantation in ways similar to younger kidney transplant recipients.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629878.001).
  • [ISSN] 1735-1308
  • [Journal-full-title] Urology journal
  • [ISO-abbreviation] Urol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


28. Posadas MA, Yang V, Ho B, Omer M, Batlle D: Acute renal failure and severe hypertension from a page kidney post-transplant biopsy. ScientificWorldJournal; 2010;10:1539-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal failure and severe hypertension from a page kidney post-transplant biopsy.
  • Page kidney refers to a clinical picture characterized by acute onset of hypertension due to external compression of the kidneys from hematoma, tumor, lymphocele, or urinoma.
  • Hypertension is believed to result from renin-angiotensin-aldosterone activation triggered by renal hypoperfusion and microvascular ischemia.
  • Renal failure, in addition to hypertension, may occur in the setting of a single functional kidney or a diseased contralateral kidney.
  • We report a case of a patient who had a transplant kidney biopsy complicated by a subcapsular perinephric hematoma.
  • The patient presented with an acute increase in blood pressure and a rapid rise in serum creatinine following a transplant kidney routine biopsy.
  • Early recognition and rapid intervention are needed in order to correct hypertension and reverse acute renal failure in Page kidney occurring in renal transplant recipients.
  • [MeSH-major] Acute Kidney Injury / physiopathology. Hematoma / physiopathology. Hypertension / physiopathology. Kidney Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694451.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Kinsey GR, Sharma R, Huang L, Li L, Vergis AL, Ye H, Ju ST, Okusa MD: Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol; 2009 Aug;20(8):1744-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury.
  • Both innate and adaptive mechanisms participate in the pathogenesis of kidney ischemia-reperfusion injury (IRI), but the role of regulatory immune mechanisms is unknown.
  • We hypothesized that the anti-inflammatory effects of CD4(+)CD25(+)FoxP3(+) regulatory T cells (Tregs) protect against renal IRI.
  • Partial depletion of Tregs with an anti-CD25 mAb potentiated kidney damage induced by IRI.
  • Reducing the number of Tregs resulted in more neutrophils, macrophages, and innate cytokine transcription in the kidney after IRI but did not affect CD4(+) T cells or B cells.
  • FoxP3(+) Treg-deficient mice accumulated a greater number of inflammatory leukocytes after renal IRI than mice containing Tregs.
  • To confirm that a lack of Tregs potentiated renal injury, we co-transferred isolated Tregs and Scurfy lymph node cells; Treg repletion significantly attenuated IRI-induced renal injury and leukocyte accumulation.
  • Furthermore, although adoptive transfer of wild-type Tregs into RAG-1 knockout mice was sufficient to prevent kidney IRI, transfer of IL-10-deficient Tregs was not.
  • Taken together, these results demonstrate that Tregs modulate injury after kidney IRI through IL-10-mediated suppression of the innate immune system.

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2005 Aug 1;175(3):1965-73 [16034141.001]
  • [Cites] Hum Immunol. 2005 Mar;66(3):222-30 [15784460.001]
  • [Cites] J Am Soc Nephrol. 2005 Nov;16(11):3315-25 [16192425.001]
  • [Cites] Trends Immunol. 2005 Dec;26(12):632-6 [16243583.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):3108-14 [16493070.001]
  • [Cites] Kidney Int. 2006 May;69(9):1601-8 [16572108.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Jun;290(6):F1516-24 [16403835.001]
  • [Cites] Nature. 2006 May 11;441(7090):235-8 [16648838.001]
  • [Cites] J Immunol. 2006 Sep 1;177(5):3380-7 [16920979.001]
  • [Cites] J Am Soc Nephrol. 2006 Oct;17(10):2731-41 [16988067.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):6780-6 [17082591.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):7155-63 [17082633.001]
  • [Cites] J Leukoc Biol. 2007 Jan;81(1):144-53 [16959895.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):416-23 [17270031.001]
  • [Cites] J Autoimmun. 2006 Dec;27(4):289-96 [17207605.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4136-46 [17371969.001]
  • [Cites] J Immunol. 2007 May 1;178(9):5899-911 [17442974.001]
  • [Cites] J Autoimmun. 2007 Aug;29(1):10-9 [17521882.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1225-32 [17449799.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1248-52 [17891146.001]
  • [Cites] J Immunol. 2008 Apr 1;180(7):4366-70 [18354156.001]
  • [Cites] Eur J Immunol. 2008 Jun;38(6):1643-53 [18493984.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):3524-34 [18714025.001]
  • [Cites] J Immunol. 2008 Nov 15;181(10):6934-41 [18981113.001]
  • [Cites] Infect Immun. 2008 Dec;76(12):5834-42 [18824539.001]
  • [Cites] Kidney Int. 2008 Dec;74(12):1526-37 [18843253.001]
  • [Cites] J Immunol. 2009 Jan 1;182(1):259-73 [19109157.001]
  • [Cites] Kidney Int. 2009 Jan;75(2):167-75 [18971925.001]
  • [Cites] Nat Med. 2009 Feb;15(2):192-9 [19169263.001]
  • [Cites] J Leukoc Biol. 2008 Dec;84(6):1400-9 [18765477.001]
  • [Cites] Annu Rev Immunol. 2001;19:683-765 [11244051.001]
  • [Cites] J Clin Invest. 2001 Nov;108(9):1283-90 [11696572.001]
  • [Cites] Kidney Int. 2001 Dec;60(6):2118-28 [11737586.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):851-7 [12235217.001]
  • [Cites] J Immunol. 2002 Nov 1;169(9):4850-60 [12391195.001]
  • [Cites] J Exp Med. 2003 Jan 6;197(1):111-9 [12515818.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]
  • [Cites] Blood. 2003 Jul 1;102(1):328-35 [12623845.001]
  • [Cites] Eur J Immunol. 2003 Aug;33(8):2090-7 [12884282.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):3210-5 [12960350.001]
  • [Cites] Arthritis Res Ther. 2004;6(5):215-22 [15380036.001]
  • [Cites] J Clin Invest. 1996 Feb 15;97(4):1056-63 [8613529.001]
  • [Cites] Am J Physiol. 1996 Mar;270(3 Pt 2):F500-9 [8780254.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2957-63 [15728508.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Apr;288(4):F722-31 [15561971.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1142-51 [16227984.001]
  • (PMID = 19497969.001).
  • [ISSN] 1533-3450
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK62324; United States / NIAMS NIH HHS / AR / AR-051203; United States / NIDDK NIH HHS / DK / DK56223; United States / NIAMS NIH HHS / AR / R01 AR051203; United States / NIDCR NIH HHS / DE / DE-017579; United States / NIDDK NIH HHS / DK / R01 DK062324; United States / NIDDK NIH HHS / DK / R01 DK056223; United States / NIDDK NIH HHS / DK / T32 DK072922; United States / NIDDK NIH HHS / DK / DK58413; United States / NIDDK NIH HHS / DK / R44 DK058413; United States / NHLBI NIH HHS / HL / P01 HL073361; United States / NIDDK NIH HHS / DK / R41 DK058413
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2 Receptor alpha Subunit; 130068-27-8 / Interleukin-10
  • [Other-IDs] NLM/ PMC2723989
  •  go-up   go-down


30. Karner CM, Chirumamilla R, Aoki S, Igarashi P, Wallingford JB, Carroll TJ: Wnt9b signaling regulates planar cell polarity and kidney tubule morphogenesis. Nat Genet; 2009 Jul;41(7):793-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wnt9b signaling regulates planar cell polarity and kidney tubule morphogenesis.
  • Although many vertebrate organs, such as kidneys, lungs and liver, are composed of epithelial tubules, little is known of the mechanisms that establish the length or diameter of these tubules.
  • In the kidney, defects in the establishment or maintenance of tubule diameter are associated with one of the most common inherited human disorders, polycystic kidney disease.
  • Here we show that attenuation of Wnt9b signaling during kidney morphogenesis affects the planar cell polarity of the epithelium and leads to tubules with significantly increased diameter.
  • Although previous studies showed that polarized cell divisions maintain the diameter of postnatal kidney tubules, we find that cell divisions are randomly oriented during embryonic development.


31. Torres PU: [What are the actual indications for a surgical parathiroidectomy?]. Nephrol Ther; 2005 Dec;1 Suppl 4:S342-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secondary hyperparathyroidism (HPTH-II) is a major complication of chronic renal insufficiency (CRI).
  • Moreover, the hyperphosphaturia induced by PTH and its stimulant effect on calcitriol synthesis and tubular calcium reabsorption are compromised by the reduction in the expression of the renal PTH receptor.
  • The chronic stimulation of PTH by these anomalies causes progressive hyperplasia of the parathyroid cells which may be transformed into a benign tumor with a monoclonal appearance.
  • [MeSH-minor] Humans. Incidence. Kidney Transplantation / physiology. Renal Dialysis / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17373206.001).
  • [ISSN] 1769-7255
  • [Journal-full-title] Néphrologie & thérapeutique
  • [ISO-abbreviation] Nephrol. Ther.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


32. Madi R, Wolf JS Jr: Single-setting bilateral hand-assisted laparoscopic partial nephrectomy. J Endourol; 2009 Jun;23(6):929-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal hilar clamping was not required, as the depth of penetration of all six tumors was only 0 to 4 mm (mean, 1.8 mm).
  • The tumor diameters ranged from 1.8 to 3.8 cm (mean, 2.4 cm).
  • Pathology revealed a benign lesion on one side and renal cell carcinoma on the other side in two patients, and bilateral leiomyomas in one patient.
  • CONCLUSION: Single-setting bilateral hand-assisted laparoscopic partial nephrectomies can be safely and effectively performed on patients with bilateral small exophytic kidney tumors.
  • We do not recommend this technique if both kidneys require temporary hilar occlusion, but it can be considered if only one kidney requires hilar occlusion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473063.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Arany I: When less is more: apoptosis during acute kidney injury. Kidney Int; 2008 Aug;74(3):261-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When less is more: apoptosis during acute kidney injury.
  • The paper by Ma and Devarajan suggests that the subtle apoptotic events that occur in the distal nephron after acute kidney injury might have a greater than expected impact on the adjacent proximal tubules and kidney function.
  • Understanding these events might facilitate development of therapeutic means to ameliorate acute kidney injury.
  • [MeSH-major] Acute Kidney Injury / pathology. Apoptosis / physiology. Reperfusion Injury / pathology
  • [MeSH-minor] Animals. Humans. Kidney / physiopathology. Kidney Tubules, Proximal / physiopathology. Nephrons / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Kidney Int. 2008 Aug;74(3):310-8 [18480747.001]
  • (PMID = 18626494.001).
  • [ISSN] 1523-1755
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Ciancio G, Burke GW 3rd: Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant; 2008 Jan;8(1):15-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab (Campath-1H) in kidney transplantation.
  • Kidney transplantation has become the treatment of choice for both the quality of life and survival in patients with end-stage renal disease (ESRD).
  • However, the immunosuppressive regimen which allows optimal kidney transplant outcome remains elusive.
  • One of the more promising induction agents, Alemtuzumab, was introduced to kidney transplantation by Calne in the late 1990s with low dose cyclosporine A monotherapy, with the hope of establishing 'prope' or near tolerance.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Graft Rejection / prevention & control. Immunosuppressive Agents / therapeutic use. Kidney Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18093269.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Immunosuppressive Agents; 3A189DH42V / alemtuzumab
  • [Number-of-references] 41
  •  go-up   go-down


35. Gómez-Ferrer Lozano A, Navarro Antón JA, Mola Arizo MJ, Polo i Peris AC: [Erythrocytosis related with hydronephrosis in a horseshoe kidney]. Actas Urol Esp; 2005 Apr;29(4):414-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Erythrocytosis related with hydronephrosis in a horseshoe kidney].
  • We report a case of a man with erythrocytosis secondary to hydronephrosis in a right horseshoe kidney.
  • Following nephrectomy of the right kidney erythrocyte count returned to normal values.
  • Secondary polyglobulia may be due to increased erythropoietine values and has been related in some patients with renal diseases such as hydronephrosis, but very rarely in association with hydronephrotic horseshoe kidney.
  • [MeSH-major] Hydronephrosis / complications. Kidney / abnormalities. Polycythemia / etiology

  • Genetic Alliance. consumer health - Horseshoe kidney.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981431.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


36. Kara C, Kutlu AO, Tosun MS, Apaydin S, Senel F: Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone. Horm Res; 2005;63(5):252-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
  • Peutz-Jeghers syndrome (PJS) is a rare disorder characterized by benign intestinal hamartomatous polyps and mucocutaneous pigmentation, and with an increased risk for intestinal and extra-intestinal neoplasms.
  • Sertoli cell tumors in boys with PJS have been increasingly recognized as a cause of prepubertal gynecomastia.
  • We report on a 7.25-year-old boy with PJS, bilateral gynecomastia, Sertoli cell tumor and nephrocalcinosis, and present the outcome of 1-year treatment with the aromatase inhibitor testolactone.
  • Histopathological examination was consistent with Sertoli cell tumors.
  • Nephrocalcinosis due to idiopathic renal hypercalciuria was also detected.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Gynecomastia / complications. Peutz-Jeghers Syndrome / complications. Sertoli Cell Tumor / complications. Testicular Neoplasms / complications. Testolactone / therapeutic use

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. TESTOLACTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947469.001).
  • [ISSN] 0301-0163
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 6J9BLA949Q / Testolactone
  •  go-up   go-down


37. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, Chung JB, Yu JS, Yoon DS: [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol; 2009 Sep;54(3):162-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas].
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has a favorable prognosis, but seems to be associated with a high incidence of extrapancreatic tumors.
  • The purpose of this study was to evaluate the incidence and clinicopathological features of extrapancreatic tumors associated with IPMN.
  • These patients were examined for the development of extrapancreatic tumors.
  • RESULTS: Of 37 patients with IPMN, 14 (38%) had 18 extrapancreatic tumors, and 10 (27%) had 13 extrapancreatic malignancies.
  • Five, six, and two extrapancreatic malignancies had been diagnosed before, during, and after the diagnosis of IPMN.
  • Gastric adenocarcinoma (3 patients, 23%) and colorectal carcinoma (3 patients, 23%) were the most common neoplasms.
  • Other extrapancreatic tumors included lung cancer (n=2), prostatic cancer (n=1), renal cell carcinoma (n=1), cholangiocellular carcinoma (n=1), urinary bladder cancer (n=1), and gallbladder cancer (n=1), respectively.
  • As benign tumor, there were two gallbladder adenoma, one gastric adenoma, one colonic adenoma and one benign ovarian cystic neoplasm, respectively.
  • CONCLUSIONS: IPMN is associated with high incidence of extrapancreatic tumors, particularly gastric and colorectal neoplasms.
  • Upper gastrointestinal endoscopy and colonoscopy should be done, and systemic surveillance for the possible occurrence of other tumors may allow early detection of extrapancreatic tumor in patients with IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Second Primary / epidemiology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2009 Sep;54(3):196-8 [19844158.001]
  • (PMID = 19844152.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


38. Rao PS, Ojo A: The alphabet soup of kidney transplantation: SCD, DCD, ECD--fundamentals for the practicing nephrologist. Clin J Am Soc Nephrol; 2009 Nov;4(11):1827-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The alphabet soup of kidney transplantation: SCD, DCD, ECD--fundamentals for the practicing nephrologist.
  • There is significant variability in the quality of deceased-donor kidneys that are used for transplantation.
  • The quality of the donor kidney has a direct effect on important clinical outcomes such as acute rejection, delayed graft function, and patient and allograft survival.
  • Expanded-criteria donors (ECDs) refer to older kidney donors (> or =60 yr) or donors who are aged 50 to 59 yr and have two of the following three features: Hypertension, terminal serum creatinine >1.5 mg/dl, or death from cerebrovascular accident.
  • By definition, ECD kidneys have a 70% greater likelihood of failure compared with one from a 35-yr-old male donor who died from a motor vehicle accident.
  • An ECD kidney transplant recipient has a projected average added-life-years of 5.1 yr compared with 10 yr for a kidney recipient from a standard-criteria donor.
  • Kidney transplantation from DCD seems to have similar allograft and patient survival compared with kidney from donation after brain death; however DCD transplantation has a 42 to 51% risk for delayed graft function (need for at least one dialysis treatment during the first week after transplantation) compared with 24% in an standard-criteria donor kidney transplant.
  • Familiarity with the comprehensive allocation rules governing different categories of deceased-donor kidneys by the nephrologists and dialysis team providers is essential to maximizing patient autonomy and to improve the outcomes of kidney transplantation.
  • [MeSH-major] Kidney Transplantation. Nephrology. Tissue Donors. Tissue and Organ Procurement


39. Tahvanainen E, Tahvanainen P, Kääriäinen H, Höckerstedt K: Polycystic liver and kidney diseases. Ann Med; 2005;37(8):546-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polycystic liver and kidney diseases.
  • There have been remarkable advances in research on polycystic liver and kidney diseases recently, covering cloning of new genes, refining disease classifications, and advances in understanding more about the molecular pathology of these diseases.
  • Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary disease affecting kidneys.
  • It affects 1/400 to 1/1000 live births and accounts for 5% of the end stage renal disease in the United States and Europe, and is caused by gene defects in the PKD1 or PKD2 genes.
  • Autosomal recessive polycystic kidney disease (ARPKD) belongs to a group of congenital hepatorenal fibrocystic syndromes.
  • [MeSH-major] Cysts / genetics. Liver Diseases / genetics. Polycystic Kidney Diseases / genetics
  • [MeSH-minor] Diagnosis, Differential. Genetic Markers. Humans. Membrane Proteins / genetics. Proteins / genetics. TRPP Cation Channels

  • Genetics Home Reference. consumer health - polycystic kidney disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338757.001).
  • [ISSN] 0785-3890
  • [Journal-full-title] Annals of medicine
  • [ISO-abbreviation] Ann. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Membrane Proteins; 0 / Proteins; 0 / SEC63 protein, human; 0 / TRPP Cation Channels; 0 / polycystic kidney disease 1 protein; 0 / polycystic kidney disease 2 protein
  • [Number-of-references] 95
  •  go-up   go-down


40. Cohen EP, Pais P, Moulder JE: Chronic kidney disease after hematopoietic stem cell transplantation. Semin Nephrol; 2010 Nov;30(6):627-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic kidney disease after hematopoietic stem cell transplantation.
  • Acute and chronic kidney diseases occur after hematopoietic stem cell transplantation.
  • Recent estimates show that near 15% of subjects undergoing hematopoietic stem cell transplantation will develop chronic kidney disease, which is a complication rate that can affect outcome and reduce survival.
  • Investigation of the causes of chronic kidney disease is needed, as are ways to prevent, mitigate, and treat it.

  • Genetic Alliance. consumer health - Kidney Disease.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Kidney Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • [Cites] J Pathol. 2000 Mar;190(4):484-8 [10699999.001]
  • [Cites] Curr Drug Targets. 2010 Nov;11(11):1423-9 [20583975.001]
  • [Cites] Radiat Res. 2002 Apr;157(4):393-401 [11893241.001]
  • [Cites] J Lab Clin Med. 2002 Apr;139(4):251-7 [12024113.001]
  • [Cites] Am J Transplant. 2003 Mar;3(3):301-5 [12614285.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2695; author reply 2695-6 [14504068.001]
  • [Cites] Pediatr Transplant. 2004 Oct;8(5):507-12 [15367289.001]
  • [Cites] N Engl J Med. 1975 Apr 17;292(16):832-43 [234595.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1501-9 [2656600.001]
  • [Cites] Nephron. 1989;51(4):555-6 [2662038.001]
  • [Cites] Kidney Int. 1989 Jun;35(6):1336-44 [2671466.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):485-94 [2300120.001]
  • [Cites] Ann Intern Med. 1991 Jan 15;114(2):113-8 [1984385.001]
  • [Cites] Ann Intern Med. 1991 Dec 15;115(12):925-30 [1952488.001]
  • [Cites] Nephron. 1993;64(4):626-35 [8366991.001]
  • [Cites] N Engl J Med. 1994 Mar 24;330(12):827-38 [8114836.001]
  • [Cites] Lab Invest. 1996 Sep;75(3):349-60 [8804358.001]
  • [Cites] Lancet. 1998 Jan 17;351(9097):178-81 [9449873.001]
  • [Cites] Bone Marrow Transplant. 1997 Dec;20(12):1069-74 [9466280.001]
  • [Cites] Nephron. 1998 Aug;79(4):408-12 [9689155.001]
  • [Cites] Int J Radiat Biol. 1999 Apr;75(4):473-9 [10331853.001]
  • [Cites] Clin Transplant. 1999 Aug;13(4):330-5 [10485375.001]
  • [Cites] Kidney Int Suppl. 2005 Aug;(97):S68-77 [16014104.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):74-9 [16173966.001]
  • [Cites] Am J Transplant. 2006 Jan;6(1):89-94 [16433761.001]
  • [Cites] Bone Marrow Transplant. 2006 Sep;38(5):351-7 [16862167.001]
  • [Cites] Semin Radiat Oncol. 2007 Apr;17(2):141-8 [17395044.001]
  • [Cites] Bone Marrow Transplant. 2007 May;39(9):571-2 [17351643.001]
  • [Cites] Nephrol Dial Transplant. 2007 May;22(5):1369-76 [17255123.001]
  • [Cites] Bone Marrow Transplant. 2007 Jun;39(11):717-23 [17401393.001]
  • [Cites] Medicine (Baltimore). 2007 Jul;86(4):215-24 [17632263.001]
  • [Cites] Clin J Am Soc Nephrol. 2007 Sep;2(5):1014-23 [17702721.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Apr;14(4):403-8 [18342782.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1546-51 [18029109.001]
  • [Cites] Nephrology (Carlton). 2008 Jun;13(4):322-30 [18221254.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jun;14(6):658-63 [18489991.001]
  • [Cites] Nephrol Dial Transplant. 2008 Aug;23(8):2700-1; author reply 2701 [18385388.001]
  • [Cites] Cancer. 2008 Oct 1;113(7):1580-7 [18704986.001]
  • [Cites] Am J Transplant. 2008 Nov;8(11):2378-90 [18925905.001]
  • [Cites] Radiat Res. 2009 Feb;171(2):164-72 [19267541.001]
  • [Cites] Radiat Res. 2009 Aug;172(2):260-4 [19630531.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Oct;15(10):1251-7 [19747632.001]
  • [Cites] Transplant Proc. 2009 Sep;41(7):2895-7 [19765466.001]
  • [Cites] Nephrol Dial Transplant. 2010 Jan;25(1):278-82 [19762604.001]
  • [Cites] Kidney Int. 2010 Feb;77(3):219-24 [19940841.001]
  • [Cites] Bone Marrow Transplant. 2010 Feb;45(2):219-34 [19584824.001]
  • [Cites] Exp Hematol. 2010 Apr;38(4):270-81 [20116413.001]
  • [Cites] Clin J Am Soc Nephrol. 2010 Jun;5(6):1107-13 [20299374.001]
  • [Cites] Clin Transplant. 2010 Jul-Aug;24(4):E94-102 [19919608.001]
  • [Cites] Radiat Res. 2001 Mar;155(3):474-80 [11182799.001]
  • (PMID = 21146127.001).
  • [ISSN] 1558-4488
  • [Journal-full-title] Seminars in nephrology
  • [ISO-abbreviation] Semin. Nephrol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U19 AI067734; United States / NIAID NIH HHS / AI / 1U19AI067734
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS249843; NLM/ PMC3005300
  •  go-up   go-down


41. Kim SS, Park HJ, Han J, Gwak SJ, Park MH, Song KW, Rhee YH, Min Chung H, Kim BS: Improvement of kidney failure with fetal kidney precursor cell transplantation. Transplantation; 2007 May 15;83(9):1249-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of kidney failure with fetal kidney precursor cell transplantation.
  • BACKGROUND: Current therapies for end-stage renal disease have severe limitations.
  • Dialysis is only a temporary treatment and does not restore kidney function.
  • Here, we show that the transplantation of fetal kidney precursor cells reconstitutes kidney tissues, reduces uremic symptoms, and provides life-saving metabolic support in kidney failure animal models.
  • METHODS: Kidney failure was surgically induced by resecting kidneys, leaving approximately 1/6 of the total kidney mass (5/6 nephrectomy).
  • Fetal kidney precursor cells were isolated from metanephroi of E17.5 rat fetuses using collagenase/dispase digestion.
  • Five weeks after the nephrectomy procedure, isolated fetal kidney precursor cells were transplanted under the kidney capsule of rats using fibrin gel matrix.
  • The cell transplantation into the kidneys of kidney failure-induced rats resulted in kidney tissue reconstitution and the transplanted cells were observed in the reconstitution region of the kidneys as evidenced by the presence of fluorescently labeled cells.
  • In addition, biochemical parameters from serum and urine samples showed improved kidney functions compared with non-treated group without severe immune response after ten weeks.
  • CONCLUSION: Transplanting fetal kidney precursor cells showed the potential for the partial augmentation of kidney structure and function in the treatment of kidney failure.
  • [MeSH-major] Embryonic Stem Cells / transplantation. Renal Insufficiency / physiopathology. Renal Insufficiency / surgery
  • [MeSH-minor] Animals. Cell Membrane. Disease Models, Animal. Disease Progression. Disease Susceptibility. Glomerulosclerosis, Focal Segmental / pathology. Glomerulosclerosis, Focal Segmental / physiopathology. Graft Rejection / etiology. Hypertrophy. Kidney / pathology. Kidney / physiopathology. Kidney Glomerulus / pathology. Kidney Glomerulus / physiopathology. Nephrectomy. Phenotype. Rats. Rats, Sprague-Dawley. Regeneration. Survival Analysis. Uremia / physiopathology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496543.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Schaeffner ES, Födinger M, Kramar R, Frei U, Hörl WH, Sunder-Plassmann G, Winkelmayer WC: Prognostic associations between lipid markers and outcomes in kidney transplant recipients. Am J Kidney Dis; 2006 Mar;47(3):509-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic associations between lipid markers and outcomes in kidney transplant recipients.
  • BACKGROUND: Hyperlipidemia is highly prevalent in kidney transplant recipients, but the prognostic significance for mortality and allograft survival in these patients has not been established sufficiently.
  • METHODS: We prospectively enrolled 733 kidney transplant recipients between 1996 and 1998.
  • Using multivariate proportional hazard regression, independent relations of fasting plasma triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol levels to risk for death from any cause and risk for kidney allograft loss were examined.
  • RESULTS: During a median follow-up of 6.1 years, 154 patients died and 260 kidney allografts were lost.
  • Further analysis of associations between high-density lipoprotein cholesterol or low-density lipoprotein cholesterol categories and patient mortality or kidney allograft loss did not show associations.
  • CONCLUSION: Elevated levels of TC or its subfractions and elevated TG levels are not associated with increased risk for patient mortality or allograft loss in these kidney transplant recipients.
  • [MeSH-major] Cholesterol / blood. Graft Survival. Kidney Transplantation

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16490631.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


43. Hostanska K, Suter A, Melzer J, Saller R: Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan) on human carcinoma cell lines. Anticancer Res; 2007 Mar-Apr;27(2):873-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Phytotherapy is a third approach for treating lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).
  • MATERIALS AND METHODS: The effect of an ethanolic extract of S. repens (10-1000 microg/ml) was tested in hormone-sensitive LNCaP, MCF-7 and hormone-insensitive DU 145, MDA MB231 prostate, breast carcinoma cell lines, renal Caki-1, urinary bladder J82, colon HCT 116 and lung A 549 cancer cells.
  • In hormone-sensitive prostate LNCaP and breast MCF-7 cell lines, the effect of extract expressed in GI50 was 2.2- and 2.5-fold more potent (p < 0.01) than in hormone-insensitive DU 145 and MDA MB231 cells.
  • [MeSH-major] Apoptosis / drug effects. Fruit / chemistry. Neoplasms / drug therapy. Phytotherapy / methods. Plant Extracts / pharmacology. Serenoa / chemistry
  • [MeSH-minor] Breast Neoplasms / drug therapy. Cell Line, Tumor. Drug Screening Assays, Antitumor. Female. HCT116 Cells. Humans. Male. Neoplasms, Hormone-Dependent / drug therapy. Prostatic Neoplasms / drug therapy


44. Paleologo G, Abdelkawy H, Barsotti M, Basha A, Bernabini G, Bianchi A, Caprio F, Emad A, Grassi G, Nerucci B, Tregnaghi C, Rizzo G, Donadio C: Kidney dimensions at sonography are correlated with glomerular filtration rate in renal transplant recipients and in kidney donors. Transplant Proc; 2007 Jul-Aug;39(6):1779-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney dimensions at sonography are correlated with glomerular filtration rate in renal transplant recipients and in kidney donors.
  • The gold standard to assess renal function is the measurement of glomerular filtration rate (GFR).
  • For practical reasons, renal function is often evaluated from serum creatinine (S Cr) or cystatin C (S Cys), and GFR is predicted from SCr.
  • Ultrasound scanning of the kidneys is used only to evaluate renal morphology.
  • The aim of this study was to evaluate the relationship between sonographic renal dimensions and GFR in renal transplant recipients and in kidney donors.
  • GFR was also predicted using the Cockcroft and Gault (CG) formula and with the simplified Modification of Diet in Renal Disease (MDRD) formula.
  • Length, width, and depth of kidneys and renal sinus were measured using renal sonography.
  • Among sonographic measurements, kidney length showed the best correlation with GFR.
  • In either case, the correlation of kidney length with GFR was greater than that of S Cr or S Cys, and similar to that of CG or MDRD GFR.
  • Accuracy of kidney length as an indicator of GFR impairment was not statistically different from laboratory tests.
  • In conclusion, renal dimensions at sonography closely correlated with GFR.
  • Thus, renal sonography can give information also on the function of the renal graft and of the remaining kidney of living donors.
  • [MeSH-major] Glomerular Filtration Rate. Kidney / anatomy & histology. Kidney / physiology. Kidney Transplantation / physiology. Tissue Donors

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692610.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CST3 protein, human; 0 / Cystatin C; 0 / Cystatins; AYI8EX34EU / Creatinine
  •  go-up   go-down


45. Zhuang WL, Wu YM, Ge SY, Mei CL: [Detection of differentially expressed genes in human autosomal dominant polycystic kidney tissue]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Dec;22(6):705-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of differentially expressed genes in human autosomal dominant polycystic kidney tissue].
  • OBJECTIVE: To detect the differentially expressed genes in human polycystic kidney by cDNA microarray.
  • Both mRNAs isolated from polycystic kidney tissue and normal kidney tissue were reversely transcribed to cDNAs with the incorporation of fluorescent dUTP (Cy5-dUTP and Cy3-dUTP) for preparing the hybridization probes.
  • RESULTS: The result indicated that the expressions of 263 genes were up regulated while the expressions of 94 genes were down regulated in the polycystic kidney tissue among the 8398 target genes.
  • Three hundred and fifty-seven differentially expressed genes with different functions were revealed in the polycystic kidney tissue, which may play some roles in the progression of polycystic kidney.
  • [MeSH-major] Gene Expression Profiling. Oligonucleotide Array Sequence Analysis / methods. Polycystic Kidney, Autosomal Dominant / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331579.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carbocyanines; 0 / DNA, Complementary; 0 / Fluorescent Dyes; 0 / cyanine dye 3; 0 / cyanine dye 5; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


46. Otsuka M, Ambiru S, Uryuhara K, Herman P, Talpe S, Dehoux JP, Jamar F, Gianello P: Early biological and immune response to semi-identical liver or kidney allograft in miniature swine. Transpl Int; 2005 Jan;18(1):78-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early biological and immune response to semi-identical liver or kidney allograft in miniature swine.
  • In inbred miniature swine, semi-identical liver allograft recipients survive up to 3 months without immunosuppression, whereas similarly mismatched kidney allografts are uniformly rejected within 2 weeks.
  • SLA(d/d) pigs (MGH, Harvard Medical School, Boston, MA, USA) received liver or kidney allograft from heterozygous SLA(c/d) miniature swine.
  • Kidney allografts were uniformly rejected within 2 weeks, whereas liver allografts survived for up to 87 days.
  • After both liver and kidney transplantation, the peripheral lymphocyte count decreased during the first week concomitantly to a significant elevation of plasma cortisol level.
  • Early decrease of peripheral platelet count was observed after liver but not renal transplantation.
  • Up-regulation of transforming growth factor beta1 (TGF-beta1) and interferon-gamma (IFN-gamma) was observed during the first postoperative week in semi-identical liver allografts and IFN-gamma as well as IL-10 in kidney allografts.
  • In liver recipients, labelled autologous lymphocytes accumulated in the liver graft and native spleen, whereas after renal allograft, lymphocytes accumulated in the native spleen and liver but never in the kidney allograft.
  • Specific cellular anti-donor unresponsiveness was observed from the first post-transplant day in both liver and kidney recipients, while the humoral anti-donor response remained intact.
  • In semi-identical liver allograft, recipient rejection is milder and slower than in similarly matched kidney allograft.
  • The rapid, nonspecific accumulation of recipient lymphocytes in the liver allograft but not in kidney allograft might also play a role in the different survival time in this model.
  • [MeSH-major] Kidney Transplantation / physiology. Liver Transplantation / physiology

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15612988.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA Primers; 0 / RNA, Messenger
  •  go-up   go-down


47. Lin F: Stem cells in kidney regeneration following acute renal injury. Pediatr Res; 2006 Apr;59(4 Pt 2):74R-8R
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cells in kidney regeneration following acute renal injury.
  • Acute renal failure has 50-80% mortality.
  • Stem cells offer an exciting potential for kidney regeneration.
  • This review discusses pathogenesis of acute renal failure resulting from ischemia-reperfusion injury and the role of stem cells in reversing or mitigating this disorder.
  • Specifically, the issues of differentiation of kidney cells from embryonic stem cells and bone marrow stem cells, and whether adult kidney stem/progenitor cells exist in the postnatal kidney are discussed.
  • Evidence to support the conclusion that intra-renal cells, including surviving tubular epithelial cells and potential renal stem/progenitor cells, are the main source for renal regeneration is provided.
  • Future research in selecting the type(s) of stem cells and optimizing the dose, frequency and route of administration of the cells will be fundamental in successful cell replacement therapy in acute renal failure.
  • Methods for enhancing endogenous renal cell proliferation and differentiation for renal repair continue to be important research directions.
  • [MeSH-major] Kidney / physiopathology. Regeneration. Stem Cells / cytology
  • [MeSH-minor] Bone Marrow Cells / cytology. Cell Differentiation. Humans. Renal Insufficiency / physiopathology. Renal Insufficiency / therapy

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549552.001).
  • [ISSN] 0031-3998
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK062839; United States / NIDDK NIH HHS / DK / R01 DK66535
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


48. Masoumi A, Reed-Gitomer B, Kelleher C, Schrier RW: Potential pharmacological interventions in polycystic kidney disease. Drugs; 2007;67(17):2495-510
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential pharmacological interventions in polycystic kidney disease.
  • Polycystic kidney diseases (autosomal dominant and autosomal recessive) are progressive renal tubular cystic diseases, which are characterised by cyst expansion and loss of normal kidney structure and function.
  • Autosomal dominant polycystic kidney disease (ADPKD) is the most common life- threatening, hereditary disease.
  • Early diagnosis and treatment of hypertension with inhibitors of the renin-angiotensin-aldosterone system (RAAS) and its potential protective effect on left ventricular hypertrophy has been one of the major therapeutic goals to decrease cardiac complications and contribute to improved prognosis of the disease.
  • Because of activation of the mammalian target of rapamycin (mTOR) pathway, the use of sirolimus (rapamycin) an mTOR inhibitor, markedly reduced cyst formation and decreased polycystic kidney size in several animal models.
  • Caspase inhibitors have been shown to decrease cytogenesis and renal failure in rats with cystic disease.
  • Cystic fluid secretion results in cyst enlargement and somatostatin analogues have been shown to decrease renal cyst progression in patients with ADPKD.
  • [MeSH-major] Polycystic Kidney Diseases / drug therapy

  • Genetic Alliance. consumer health - Kidney Disease.
  • Genetic Alliance. consumer health - Polycystic Kidney Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2006 Aug;17(8):2220-7 [16807403.001]
  • [Cites] Kidney Int. 2002 Apr;61(4):1220-30 [11918728.001]
  • [Cites] Adv Cancer Res. 2000;77:25-79 [10549355.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7037-44 [11416184.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9260-5 [12082174.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13254-9 [12239346.001]
  • [Cites] Mamm Genome. 2003 Apr;14(4):242-9 [12682776.001]
  • [Cites] J Am Soc Nephrol. 1997 Aug;8(8):1292-7 [9259356.001]
  • [Cites] Science. 1998 Apr 3;280(5360):32-4 [9556450.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):4984-96 [12077328.001]
  • [Cites] Kidney Int. 1991 Jan;39(1):57-62 [2002633.001]
  • [Cites] Cell Signal. 2003 May;15(5):463-9 [12639709.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 23;282(1):341-50 [11264013.001]
  • [Cites] Am J Physiol. 1991 Dec;261(6 Pt 2):F951-6 [1661085.001]
  • [Cites] Cell Signal. 1999 Sep;11(9):651-63 [10530873.001]
  • [Cites] J Am Soc Nephrol. 2001 Feb;12(2):379-84 [11158230.001]
  • [Cites] Kidney Int. 1996 Oct;50(4):1327-36 [8887295.001]
  • [Cites] Am J Kidney Dis. 1994 Oct;24(4):561-8 [7942810.001]
  • [Cites] Am J Physiol. 1995 Aug;269(2 Pt 1):C487-95 [7653531.001]
  • [Cites] J Clin Invest. 1997 Mar 15;99(6):1380-9 [9077548.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20451-7 [11278652.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Feb;272(2):546-51 [7853167.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1374-83 [15336986.001]
  • [Cites] Kidney Int. 2004 Sep;66(3):964-73 [15327388.001]
  • [Cites] Dev Cell. 2003 May;4(5):753-9 [12737809.001]
  • [Cites] Kidney Int. 1989 Feb;35(2):675-80 [2709672.001]
  • [Cites] Adv Nephrol Necker Hosp. 1998;28:439-78 [9890004.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1432-7 [9465032.001]
  • [Cites] Kidney Int. 2005 Mar;67(3):909-19 [15698430.001]
  • [Cites] J Am Soc Nephrol. 2002 Sep;13(9):2384-98 [12191984.001]
  • [Cites] FASEB J. 2001 Nov;15(13):2536-8 [11641256.001]
  • [Cites] J Cell Biochem. 2002;86(1):21-8 [12112012.001]
  • [Cites] Curr Biol. 2002 Jun 4;12(11):R378-80 [12062067.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Jan;33(1):7-23 [10714959.001]
  • [Cites] Methods. 2003 Jul;30(3):191-7 [12798133.001]
  • [Cites] Kidney Int. 1999 Jan;55(1):29-62 [9893113.001]
  • [Cites] J Urol. 1998 Jan;159(1):291-6 [9400497.001]
  • [Cites] J Am Soc Nephrol. 2003 Feb;14 (2):367-76 [12538737.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 Nov;285(5):F998-F1012 [12837680.001]
  • [Cites] J Am Soc Nephrol. 2000 Jul;11(7):1179-87 [10864573.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):821-8 [9563874.001]
  • [Cites] Kidney Int. 2000 Apr;57(4):1460-71 [10760082.001]
  • [Cites] Pediatrics. 2003 May;111(5 Pt 1):1072-80 [12728091.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Dec 30;197(3):1083-93 [8280123.001]
  • [Cites] J Am Soc Nephrol. 1993 Jan;3(7):1378-86 [8094982.001]
  • [Cites] J Membr Biol. 2001 Nov 1;184(1):71-9 [11687880.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29728-39 [15123714.001]
  • [Cites] Nat Genet. 2005 May;37(5):537-43 [15852005.001]
  • [Cites] Circulation. 2001 May 15;103(19):2387-94 [11352889.001]
  • [Cites] Kidney Int. 2005 Jul;68(1):206-16 [15954910.001]
  • [Cites] Kidney Int. 1988 Nov;34(5):683-90 [2974094.001]
  • [Cites] Am J Kidney Dis. 1996 Dec;28(6):788-803 [8957030.001]
  • [Cites] Am J Kidney Dis. 1997 Nov;30(5):703-9 [9370187.001]
  • [Cites] Pol Arch Med Wewn. 1996 Oct;96(4):329-43 [9082344.001]
  • [Cites] Physiol Rev. 1998 Oct;78(4):1165-91 [9790573.001]
  • [Cites] Cell. 2004 Jun 11;117(6):693-7 [15186771.001]
  • [Cites] J Clin Invest. 2000 Jan;105(1):9-13 [10619855.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Oct;287(4):F775-88 [15187005.001]
  • [Cites] J Pediatr. 1987 May;110(5):729-34 [2883274.001]
  • [Cites] Kidney Int. 1992 Jan;41(1):206-10 [1317477.001]
  • [Cites] J Clin Invest. 1998 Mar 1;101(5):935-9 [9486961.001]
  • [Cites] Kidney Int. 2005 Apr;67(4):1234-47 [15780076.001]
  • [Cites] J Cell Sci. 2003 Apr 15;116(Pt 8):1519-25 [12640036.001]
  • [Cites] J Am Soc Nephrol. 2002 Oct;13(10):2508-16 [12239239.001]
  • [Cites] Kidney Int. 1992 Aug;42(2):364-73 [1405319.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):554-9 [9435230.001]
  • [Cites] J Clin Invest. 2002 Oct;110(8):1083-91 [12393844.001]
  • [Cites] Semin Nephrol. 1991 Nov;11(6):653-60 [1767138.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):129-37 [12514735.001]
  • [Cites] J Am Soc Nephrol. 1993 Oct;4(4):1064-72 [7904485.001]
  • [Cites] Kidney Int. 1988 Jun;33(6):1084-90 [3043076.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5286-91 [12672950.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7320-6 [11058599.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Dec;283(6):F1313-25 [12388409.001]
  • [Cites] Trends Cell Biol. 2004 Feb;14 (2):78-85 [15102439.001]
  • [Cites] Oncogene. 1999 Nov 11;18(47):6505-12 [10597253.001]
  • [Cites] J Am Soc Nephrol. 2005 Jan;16(1):46-51 [15563559.001]
  • [Cites] Am J Physiol. 1998 Sep;275(3 Pt 2):F387-94 [9729511.001]
  • [Cites] Hum Mol Genet. 2003 Aug 1;12(15):1875-80 [12874107.001]
  • [Cites] Nat Genet. 1995 Jun;10(2):151-60 [7663510.001]
  • [Cites] Nat Med. 2004 Apr;10(4):363-4 [14991049.001]
  • [Cites] Circ Res. 2005 Apr 29;96(8):873-80 [15790956.001]
  • [Cites] FASEB J. 2004 May;18(7):884-6 [15001556.001]
  • [Cites] Curr Biol. 2001 May 1;11(9):R356-60 [11369247.001]
  • [Cites] Mayo Clin Proc. 1991 Oct;66(10):1010-7 [1921483.001]
  • [Cites] J Clin Invest. 2004 Mar;113(6):814-25 [15067314.001]
  • [Cites] Oncogene. 1998 Sep 17;17(11 Reviews):1395-413 [9779987.001]
  • [Cites] J Anat. 2001 Oct;199(Pt 4):393-405 [11693300.001]
  • [Cites] J Am Soc Nephrol. 2005 Apr;16(4):846-51 [15728778.001]
  • [Cites] N Engl J Med. 2004 Jan 8;350(2):151-64 [14711914.001]
  • [Cites] J Am Soc Nephrol. 2002 Nov;13(11):2723-9 [12397042.001]
  • [Cites] J Biol Chem. 1997 Jul 18;272(29):17907-11 [9218414.001]
  • [Cites] J Biol Chem. 2000 Oct 13;275(41):31921-9 [10931830.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3423-34 [10207066.001]
  • [Cites] Kidney Int. 2003 Nov;64(5):1792-9 [14531813.001]
  • [Cites] Am J Kidney Dis. 1995 Sep;26(3):501-7 [7645559.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6241-8 [10339572.001]
  • [Cites] Trends Biochem Sci. 2004 Jan;29(1):32-8 [14729330.001]
  • [Cites] Lab Invest. 1974 Oct;31(4):303-13 [4412080.001]
  • [Cites] Hum Mol Genet. 2003 Oct 15;12(20):2703-10 [12925574.001]
  • [Cites] Dev Biol. 1990 Mar;138(1):225-30 [1968405.001]
  • [Cites] Am J Nephrol. 1985;5(3):176-81 [3893129.001]
  • [Cites] J Am Soc Nephrol. 1994 Dec;5(6):1349-54 [7894001.001]
  • [Cites] Nephron. 1979;24(4):198-204 [40149.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):354-9 [7812968.001]
  • [Cites] J Am Soc Nephrol. 1998 May;9(5):903-16 [9596091.001]
  • [Cites] Genes Dev. 2002 Jun 15;16(12 ):1472-87 [12080086.001]
  • [Cites] Am J Kidney Dis. 2000 Mar;35(3):427-32 [10692268.001]
  • [Cites] Am J Physiol. 1999 Jun;276(6 Pt 2):F837-46 [10362772.001]
  • [Cites] EMBO J. 2004 Apr 7;23(7):1657-68 [15029248.001]
  • [Cites] N Engl J Med. 1990 Oct 18;323(16):1091-6 [2215576.001]
  • [Cites] J Clin Endocrinol Metab. 1987 May;64(5):975-9 [2881944.001]
  • [Cites] N Engl J Med. 1983 Dec 15;309(24):1495-501 [6139753.001]
  • [Cites] Exp Toxicol Pathol. 2001 Jun;53(2-3):123-8 [11484829.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11960-5 [11035810.001]
  • [Cites] Br Med J (Clin Res Ed). 1986 Jun 28;292(6537):1701-2 [2873863.001]
  • [Cites] Kidney Int. 1995 Feb;47(2):490-9 [7723235.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3700-4 [8170972.001]
  • [Cites] Mol Cell. 2001 Apr;7(4):823-32 [11336705.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):19-24 [15624019.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):2807-18 [12429740.001]
  • [Cites] Cell. 2000 Jul 7;102(1):1-4 [10929706.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1089-95 [9334719.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2975-83 [14593099.001]
  • [Cites] J Clin Invest. 2001 May;107(9):1145-52 [11342578.001]
  • [Cites] Physiol Rev. 1997 Jan;77(1):75-197 [9016301.001]
  • [Cites] J Am Soc Nephrol. 1998 Jul;9(7):1169-77 [9644626.001]
  • [Cites] Kidney Int. 2000 Jan;57(1):33-40 [10620185.001]
  • [Cites] Physiol Res. 2004;53(6):629-34 [15588131.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):785-9 [8524413.001]
  • [Cites] J Hypertens. 1997 Sep;15(9):925-33 [9321739.001]
  • [Cites] Cell Calcium. 2005 Jun;37(6):593-601 [15862350.001]
  • [Cites] Science. 2002 Aug 23;297(5585):1352-4 [12193789.001]
  • [Cites] Oncogene. 1996 Sep 19;13(6):1153-60 [8808689.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9666-70 [11493700.001]
  • [Cites] Kidney Int. 1992 May;41(5):1222-36 [1319521.001]
  • [Cites] Clin Nephrol. 1975;3(3):99-105 [1139805.001]
  • [Cites] Biochim Biophys Acta. 1999 May 31;1423(3):C19-30 [10382537.001]
  • [Cites] Contrib Nephrol. 1995;115:118-21 [8585897.001]
  • [Cites] Kidney Int. 1972 Aug;2(2):107-13 [4671535.001]
  • [Cites] Transplantation. 2002 Oct 27;74(8):1070-6 [12438948.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3934-9 [10097141.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6954-9 [15863619.001]
  • [Cites] Am J Nephrol. 1998;18(5):391-8 [9730562.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1267-73 [11106764.001]
  • [Cites] Biol Cell. 2001 Sep;93(1-2):53-62 [11730323.001]
  • [Cites] J Am Soc Nephrol. 2000 Aug;11(8):1505-11 [10906164.001]
  • [Cites] J Urol. 1969 Aug;102(2):156-61 [5796888.001]
  • [Cites] J Natl Cancer Inst. 1998 Jul 15;90(14):1087-94 [9672257.001]
  • [Cites] J Am Soc Nephrol. 1995 Jun;5(12):2048-56 [7579053.001]
  • [Cites] Kidney Int. 2003 Jun;63(6):1983-94 [12753285.001]
  • [Cites] Pediatr Nephrol. 1988 Jul;2(3):296-302 [3153029.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1182-7 [11252306.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Nov;77(5):1323-8 [7915721.001]
  • [Cites] Cell. 2003 Jul 11;114(1):61-73 [12859898.001]
  • [Cites] J Am Soc Nephrol. 2002 Jul;13(7):1733-9 [12089368.001]
  • [Cites] Nat Cell Biol. 2002 Mar;4(3):191-7 [11854751.001]
  • [Cites] Nat Med. 2003 Oct;9(10):1323-6 [14502283.001]
  • [Cites] Kidney Blood Press Res. 2006;29(3):182-8 [16943682.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):1051-60 [8097368.001]
  • [Cites] Kidney Int. 2003 Nov;64(5):1573-9 [14531789.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6666-78 [9774681.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 1):578-83 [7861486.001]
  • [Cites] Kidney Int. 2004 Nov;66(5):1766-73 [15496147.001]
  • [Cites] Am J Nephrol. 2001 Mar-Apr;21(2):98-103 [11359016.001]
  • [Cites] JAMA. 1991 Feb 20;265(7):888-92 [1992187.001]
  • [Cites] J Biol Chem. 1995 Jan 20;270(3):1149-55 [7836373.001]
  • [Cites] Nephrol Dial Transplant. 1999 May;14(5):1113-6 [10344347.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1719-30 [15509540.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5466-71 [16567633.001]
  • [Cites] Acta Med Scand. 1986;219(4):399-405 [3716882.001]
  • [Cites] Arch Dermatol Res. 2004 Jul;296(2):74-82 [15278365.001]
  • [Cites] Curr Opin Pharmacol. 2003 Aug;3(4):371-7 [12901945.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5645-50 [12384518.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):18-25 [7776989.001]
  • [Cites] Kidney Int. 1996 Jan;49(1):135-46 [8770959.001]
  • (PMID = 18034588.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / U01 DK624
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 190
  •  go-up   go-down


49. Longenecker CT, Scherzer R, Bacchetti P, Lewis CE, Grunfeld C, Shlipak MG: HIV viremia and changes in kidney function. AIDS; 2009 Jun 1;23(9):1089-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV viremia and changes in kidney function.
  • OBJECTIVE: To evaluate the effect of HIV infection on longitudinal changes in kidney function and to identify independent predictors of kidney function changes in HIV-infected individuals.
  • CONCLUSION: Compared with controls, HIV-infected persons were more likely both to have clinical decline and clinical improvement in kidney function during 5 years of follow-up.
  • The extent of viremic control had a strong association with longitudinal changes in kidney function.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2006 Jan;17(1):254-61 [16267155.001]
  • [Cites] J Am Soc Nephrol. 2005 May;16(5):1404-12 [15788478.001]
  • [Cites] Antivir Ther. 2006;11(5):641-5 [16964834.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2283-96 [17135583.001]
  • [Cites] AIDS. 2007 May 11;21(8):1003-9 [17457094.001]
  • [Cites] AIDS. 2007 May 31;21(9):1119-27 [17502722.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Jan;1(1):117-29 [17699198.001]
  • [Cites] Nephrol Dial Transplant. 2007 Nov;22(11):3186-90 [17575315.001]
  • [Cites] Arch Intern Med. 2007 Nov 12;167(20):2213-9 [17998494.001]
  • [Cites] Kidney Int. 2007 Dec;72(11):1380-7 [17805235.001]
  • [Cites] AIDS. 2007 Nov 30;21(18):2435-43 [18025880.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jan;93(1):216-24 [17940113.001]
  • [Cites] Am J Med Sci. 2008 Feb;335(2):89-94 [18277114.001]
  • [Cites] Am J Kidney Dis. 2008 Mar;51(3):395-406 [18295055.001]
  • [Cites] AIDS. 2008 Feb 19;22(4):481-7 [18301060.001]
  • [Cites] Clin Infect Dis. 2008 Apr 15;46(8):1271-81 [18444867.001]
  • [Cites] Am J Kidney Dis. 2008 Jun;51(6):914-24 [18455851.001]
  • [Cites] Arch Intern Med. 2008 Nov 10;168(20):2212-8 [19001197.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):71-82 [19050388.001]
  • [Cites] Kidney Int. 2009 Feb;75(4):428-34 [19052538.001]
  • [Cites] Am J Nephrol. 2009;30(3):171-8 [19349699.001]
  • [Cites] Biometrics. 2000 Sep;56(3):779-88 [10985216.001]
  • [Cites] Am J Kidney Dis. 2002 Aug;40(2):221-6 [12148093.001]
  • [Cites] J Am Soc Nephrol. 2002 Dec;13(12):2997-3004 [12444220.001]
  • [Cites] AIDS. 2004 Feb 20;18(3):541-6 [15090808.001]
  • [Cites] Kidney Int. 2004 Sep;66(3):1145-52 [15327410.001]
  • [Cites] J Clin Epidemiol. 1988;41(11):1105-16 [3204420.001]
  • [Cites] Am J Nephrol. 1995;15(3):217-21 [7618646.001]
  • [Cites] Kidney Int. 1995 Aug;48(2):311-20 [7564098.001]
  • [Cites] Scand J Clin Lab Invest. 1999 Feb;59(1):1-8 [10206092.001]
  • [Cites] Stat Methods Med Res. 1999 Mar;8(1):3-15 [10347857.001]
  • [Cites] J Am Soc Nephrol. 2004 Dec;15(12):3184-91 [15579522.001]
  • [Cites] J Am Soc Nephrol. 2005 Feb;16(2):459-66 [15615823.001]
  • [Cites] Am J Epidemiol. 2006 May 1;163(9):860-9 [16524955.001]
  • (PMID = 19352136.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01-HL-74814; United States / NIDDK NIH HHS / DK / R01 DK057508-01S1; United States / NCRR NIH HHS / RR / M01 RR000083-38S30468; United States / NIDDK NIH HHS / DK / R01 DK057508; United States / NCRR NIH HHS / RR / M01-RR00083; United States / NHLBI NIH HHS / HL / R01 HL074814-07; United States / NIDDK NIH HHS / DK / R01 DK057508-01; United States / NCRR NIH HHS / RR / M01 RR000083-380468; United States / NCRR NIH HHS / RR / M01 RR000083-40S10468; United States / NCRR NIH HHS / RR / M01 RR000083-430512; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCRR NIH HHS / RR / M01 RR000036; United States / NHLBI NIH HHS / HL / R01 HL074814-04; United States / NCRR NIH HHS / RR / M01 RR000083-38S20468; United States / NCRR NIH HHS / RR / M01 RR000083-420512; United States / NHLBI NIH HHS / HL / R01 HL074814-06; United States / NIDDK NIH HHS / DK / R01 DK057508-03S1; United States / NCRR NIH HHS / RR / M01 RR000054; United States / NCRR NIH HHS / RR / M01-RR00052; United States / NIDDK NIH HHS / DK / R01 DK057508-03S2; United States / NCRR NIH HHS / RR / M01 RR000052; United States / NHLBI NIH HHS / HL / R01 HL074814-05; United States / NCRR NIH HHS / RR / M01 RR000051; United States / NCRR NIH HHS / RR / M01-RR00051; United States / NCRR NIH HHS / RR / M01-RR00036; United States / NHLBI NIH HHS / HL / R01 HL074814; United States / NIDDK NIH HHS / DK / R01 DK057508-02; United States / NCRR NIH HHS / RR / M01 RR000083-400468; United States / NHLBI NIH HHS / HL / R01-HL-53359; United States / NCRR NIH HHS / RR / M01-RR00636; United States / NCRR NIH HHS / RR / M01 RR000083-390468; United States / NCRR NIH HHS / RR / M01-RR00054; United States / NCRR NIH HHS / RR / M01 RR000083; United States / NIDDK NIH HHS / DK / R01 DK057508-03; United States / NIDDK NIH HHS / DK / R01-DK-57508
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cystatin C
  • [Other-IDs] NLM/ NIHMS492632; NLM/ PMC3725756
  •  go-up   go-down


50. Goldstein SL, Devarajan P: Progression from acute kidney injury to chronic kidney disease: a pediatric perspective. Adv Chronic Kidney Dis; 2008 Jul;15(3):278-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression from acute kidney injury to chronic kidney disease: a pediatric perspective.
  • Although emerging evidence indicates that the incidence of both acute kidney injury (AKI) and chronic kidney disease (CKD) in children is rising and the etiologies are dramatically changing, relatively little is currently known regarding the potential for transition from AKI to CKD.
  • These include neutrophil gelatinase-associated lipocalin, liver-type fatty acid-binding protein, and kidney injury molecule-1.

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Chronic Kidney Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nephrol Dial Transplant. 2008 Jan;23(1):414-6 [17893105.001]
  • [Cites] Transplantation. 2007 Dec 27;84(12):1625-30 [18165774.001]
  • [Cites] Kidney Int. 2008 Feb;73(4):465-72 [18094680.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2008 Mar;17(2):127-32 [18277143.001]
  • [Cites] Crit Care. 2007;11(6):R127 [18070344.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 May;3(3):665-73 [18337554.001]
  • [Cites] Pediatr Crit Care Med. 2008 May;9(3):279-84 [18446113.001]
  • [Cites] Adv Chronic Kidney Dis. 2008 Jul;15(3):222-34 [18565474.001]
  • [Cites] Pediatr Nephrol. 2000 Nov;15(1-2):11-3 [11095002.001]
  • [Cites] Curr Opin Pediatr. 2002 Apr;14(2):183-8 [11981288.001]
  • [Cites] Kidney Int. 2002 Jul;62(1):237-44 [12081583.001]
  • [Cites] Crit Care Med. 2002 Sep;30(9):2156-7 [12352064.001]
  • [Cites] Pediatr Nephrol. 2002 Dec;17(12):1032-7 [12478353.001]
  • [Cites] Kidney Int. 2003 May;63(5):1714-24 [12675847.001]
  • [Cites] Pediatr Nephrol. 2003 Aug;18(8):796-804 [12811650.001]
  • [Cites] J Am Soc Nephrol. 2003 Oct;14(10):2534-43 [14514731.001]
  • [Cites] Ann Thorac Surg. 2003 Nov;76(5):1443-9 [14602265.001]
  • [Cites] Pediatr Nephrol. 2004 Jan;19(1):91-5 [14634863.001]
  • [Cites] Am J Nephrol. 2004 May-Jun;24(3):307-15 [15148457.001]
  • [Cites] Crit Care. 2004 Aug;8(4):R204-12 [15312219.001]
  • [Cites] Am J Kidney Dis. 1995 Jan;25(1):113-8 [7810517.001]
  • [Cites] Am J Kidney Dis. 2005 Jan;45(1):96-101 [15696448.001]
  • [Cites] Lancet. 2005 Apr 2-8;365(9466):1231-8 [15811456.001]
  • [Cites] J Am Soc Nephrol. 2005 Nov;16(11):3365-70 [16177006.001]
  • [Cites] Am J Kidney Dis. 2005 Dec;46(6):1038-48 [16310569.001]
  • [Cites] J Am Soc Nephrol. 2005 Dec;16(12):3736-41 [16267160.001]
  • [Cites] Kidney Int. 2006 Jan;69(1):184-9 [16374442.001]
  • [Cites] Ann Thorac Surg. 2006 Feb;81(2):542-6 [16427848.001]
  • [Cites] Mol Cell Biochem. 2006 Mar;284(1-2):175-82 [16532260.001]
  • [Cites] Pediatr Nephrol. 2006 Jun;21(6):856-63 [16528543.001]
  • [Cites] Pediatr Nephrol. 2006 Jul;21(7):989-94 [16773412.001]
  • [Cites] Crit Care Med. 2006 Jul;34(7):1913-7 [16715038.001]
  • [Cites] Am J Transplant. 2006 Jul;6(7):1639-45 [16827865.001]
  • [Cites] Crit Care. 2006;10(3):R73 [16696865.001]
  • [Cites] Arthritis Rheum. 2006 Aug;54(8):2577-84 [16868980.001]
  • [Cites] Pediatrics. 2006 Sep;118(3):e786-91 [16894011.001]
  • [Cites] Pediatr Nephrol. 2007 Jan;22(1):101-8 [17072653.001]
  • [Cites] Pediatr Crit Care Med. 2007 Jan;8(1):29-35 [17251879.001]
  • [Cites] Clin Immunol. 2007 May;123(2):227-34 [17360238.001]
  • [Cites] Kidney Int. 2007 May;71(10):1028-35 [17396113.001]
  • [Cites] J Pathol. 2007 Jun;212(2):209-17 [17471468.001]
  • [Cites] Am J Nephrol. 2007;27(4):373-8 [17570904.001]
  • [Cites] Kidney Int. 2007 Aug;72(3):348-58 [17495861.001]
  • [Cites] Am J Kidney Dis. 2007 Aug;50(2):169-80 [17660017.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Sep;1(5):1006-15 [17699320.001]
  • [Cites] J Am Soc Nephrol. 2007 Oct;18(10):2704-14 [17898236.001]
  • [Cites] J Am Soc Nephrol. 2007 Nov;18(11):2894-902 [17942962.001]
  • [Cites] Pediatr Nephrol. 2007 Dec;22(12):2089-95 [17874137.001]
  • [Cites] Semin Nephrol. 2007 Nov;27(6):637-51 [18061846.001]
  • [Cites] Crit Care. 2007;11(4):R84 [17678545.001]
  • (PMID = 18565478.001).
  • [ISSN] 1548-5609
  • [Journal-full-title] Advances in chronic kidney disease
  • [ISO-abbreviation] Adv Chronic Kidney Dis
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK069749-04; United States / NIDDK NIH HHS / DK / DK069749-04; United States / NIDDK NIH HHS / DK / R21 DK070163-02; United States / NIDDK NIH HHS / DK / R01 DK069749; United States / NIDDK NIH HHS / DK / R21 DK070163
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 54
  • [Other-IDs] NLM/ NIHMS57871; NLM/ PMC2481383
  •  go-up   go-down


51. Doctor RB, Serkova NJ, Hasebroock KM, Zafar I, Edelstein CL: Distinct patterns of kidney and liver cyst growth in pkd2(WS25/-) mice. Nephrol Dial Transplant; 2010 Nov;25(11):3496-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct patterns of kidney and liver cyst growth in pkd2(WS25/-) mice.
  • BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disease that results in the development of cystic kidneys and liver.
  • Providing the foundation for future long-term studies, the present work documents distinct patterns of long-term cyst growth in the kidneys and liver of male and female pkd2(WS25/-) mice.
  • METHODS: Gravimetric measurements documented the progression of kidney and liver growth in male and female pkd2(WS25/-) mice over 12 months.
  • A fast imaging with steady-state precision-magnetic resonance imaging (FISP-MRI) technique to measure kidney and liver organ and cyst volumes was optimized and validated.
  • RESULTS: Male and female pkd2(WS25/-) mice had significant increases in kidney weights after 4 months of age.
  • The progression of kidney growth was minimal after 4 months of age.
  • CONCLUSIONS: Pkd2(WS25/-) mice are a genetic mouse model that recapitulates the early phenotypic characteristics of human ADPKD kidney cystogenesis.

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1988 Nov-Dec;8(6):1627-34 [3192176.001]
  • [Cites] Kidney Int. 2004 Apr;65(4):1511-6 [15086495.001]
  • [Cites] Magn Reson Imaging. 1991;9(3):429-34 [1881263.001]
  • [Cites] Hepatology. 1997 Nov;26(5):1282-6 [9362373.001]
  • [Cites] Cell. 1998 Apr 17;93(2):177-88 [9568711.001]
  • [Cites] N Engl J Med. 2006 May 18;354(20):2122-30 [16707749.001]
  • [Cites] Nephron Clin Pract. 2006;103(4):c173-80 [16636585.001]
  • [Cites] J Magn Reson Imaging. 2006 Sep;24(3):646-56 [16878308.001]
  • [Cites] N Engl J Med. 2007 Apr 12;356(15):1560 [17429087.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Jan;1(1):64-9 [17699192.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6450-8 [17975157.001]
  • [Cites] Kidney Int. 2008 Mar;73(6):778-81 [18185504.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2008 Jul;295(1):L152-61 [18441091.001]
  • [Cites] AJR Am J Roentgenol. 2008 Aug;191(2):352-8 [18647901.001]
  • [Cites] N Engl J Med. 2008 Oct 2;359(14):1477-85 [18832246.001]
  • [Cites] Acad Radiol. 2009 Jan;16(1):88-95 [19064216.001]
  • [Cites] Kidney Int. 2009 Jan;75(2):235-41 [18971924.001]
  • [Cites] J Am Soc Nephrol. 2009 Jan;20(1):6-8 [19073819.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):36-53 [19149687.001]
  • [Cites] Annu Rev Med. 2009;60:321-37 [18947299.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):75-8 [10615132.001]
  • [Cites] J Am Soc Nephrol. 2000 Aug;11(8):1505-11 [10906164.001]
  • [Cites] Kidney Int. 2000 Dec;58(6):2492-501 [11115083.001]
  • [Cites] Comp Med. 2002 Oct;52(5):433-8 [12405636.001]
  • [Cites] J Magn Reson Imaging. 2003 Feb;17(2):190-6 [12541226.001]
  • [Cites] Kidney Int. 2003 Sep;64(3):1035-45 [12911554.001]
  • [Cites] Hepatology. 1990 Jun;11(6):1033-7 [2365280.001]
  • (PMID = 20388629.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK-074835; United States / NCRR NIH HHS / RR / UL1 RR025780; United States / NIDDK NIH HHS / DK / R01 DK074835; United States / NCI NIH HHS / CA / P30 CA046934; United States / NIDDK NIH HHS / DK / DK-056851; United States / NIDDK NIH HHS / DK / R01 DK056851
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TRPP Cation Channels; 0 / polycystic kidney disease 2 protein
  • [Other-IDs] NLM/ PMC2980992
  •  go-up   go-down


52. Collan Y, Hirsimäki P, Aho H, Wuorela M, Sundström J, Tertti R, Metsärinne K: Value of electron microscopy in kidney biopsy diagnosis. Ultrastruct Pathol; 2005 Nov-Dec;29(6):461-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of electron microscopy in kidney biopsy diagnosis.
  • Kidney biopsy reports given during 2003 were collected from the authors' pathology database.
  • Five tumor samples were not studied with electron microscopy (EM).
  • EM was not performed in 10/24 transplant biopsies, or in 11/82 cases of suspected primary kidney disease.
  • (1) EM was essential for diagnosis, (2) EM contributed to the interpretation and cleared uncertainties, and (3) EM had no influence on the diagnostic process.
  • In transplant biopsies EM influenced the final diagnosis in 86% of cases (category 2).
  • In biopsies performed for primary kidney disease EM was essential for diagnosis in 18.3% clearly contributed in 53.5%, and had no influence on the final diagnosis in 28.2% of cases.
  • Because only about 25% of the EM reports did not have any influence on the diagnostic process, it is recommended that kidney biopsy protocols should include EM in all biopsy cases, or at least tissue should be reserved for EM studies of all cases.
  • [MeSH-major] Kidney / ultrastructure. Kidney Diseases / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy. Diagnosis, Differential. Humans. Kidney Transplantation / pathology. Male. Microscopy, Electron, Transmission

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16316946.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Rodrigo E, Arias M: A practical approach to immune monitoring in kidney transplantation. Minerva Urol Nefrol; 2007 Sep;59(3):337-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A practical approach to immune monitoring in kidney transplantation.
  • In the last years, there has been a growing interest in the development of new assays available to monitor kidney transplantation.
  • These assays will permit strategies for the minimization of immunosuppression, for induction of operational tolerance, for an early and noninvasive diagnosis of acute rejection, for prevention of adverse effects of immunosuppressive drugs and for measurement of the net immunosuppressive state.
  • Today, there is not one test that helps us monitor the outcome of kidney recipients safely.
  • Further studies and further developed assays are needed to obtain an adequate immune monitoring strategy in kidney transplantation.
  • Transvivo DTH assay, tetramer staining, quantification of cell proliferation by CFSE labelling, human leukocyte antigen-G determination, phenotyping of recipient immune cells, detection of tolerogeneic dendritic cell precursors, T-cell receptor landscaping and quantification of gene and protein expression need more studies to know their exact role as monitoring markers in kidney transplant patients.
  • [MeSH-major] Kidney Transplantation / immunology. Monitoring, Immunologic

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17912229.001).
  • [ISSN] 0393-2249
  • [Journal-full-title] Minerva urologica e nefrologica = The Italian journal of urology and nephrology
  • [ISO-abbreviation] Minerva Urol Nefrol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 96
  •  go-up   go-down


54. Feyssa E, Jones-Burton C, Ellison G, Philosophe B, Howell C: Racial/ethnic disparity in kidney transplantation outcomes: influence of donor and recipient characteristics. J Natl Med Assoc; 2009 Feb;101(2):111-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial/ethnic disparity in kidney transplantation outcomes: influence of donor and recipient characteristics.
  • OBJECTIVE: The purpose of this study was to evaluate the basis for the racial/ethnic disparity in kidney allograft survival.
  • METHODS: We conducted a retrospective study of 2130 patients who underwent kidney transplantation between January 1995 and December 2003.
  • Additionally, black recipients were more likely to have a prior kidney transplant (16.7% vs 11.0%) and to have a cadaver kidney donor (74% vs 56.5%).
  • Previous kidney transplantation, cadaveric donor, donor age, recipient employment status, and recipient tobacco use were associated with allograft survival in a Cox proportional hazard model.
  • CONCLUSIONS: Graft survival rate in black kidney transplant recipients is significantly lower than whites, and this disparity can be partially explained by the low rate of live donors and a higher previous transplantation rate in blacks.
  • [MeSH-major] Graft Survival. Healthcare Disparities / statistics & numerical data. Kidney Transplantation / ethnology. Kidney Transplantation / immunology


55. Hirsch S: Prerenal success in chronic kidney disease. Am J Med; 2007 Sep;120(9):754-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prerenal success in chronic kidney disease.
  • Renin-angiotensin system inhibitors and diuretics are commonly prescribed to patients with chronic kidney disease to reduce systemic blood pressure.
  • Several reasons for this reluctance are discussed, including the failure to distinguish between hemodynamic- and parenchymal-mediated changes in kidney function.
  • Finally, recent literature describing harmful effects of increases in serum creatinine in other cohorts is reviewed; these cohorts are sufficiently different from the stable chronic kidney disease patient that the results ought not to be extrapolated.
  • [MeSH-major] Renal Insufficiency, Chronic / physiopathology

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Chronic Kidney Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765040.001).
  • [ISSN] 1555-7162
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  • [Number-of-references] 36
  •  go-up   go-down


56. Gheith OA, El-Saadany SA, Abuo Donia SA, Salem YM: Compliance of kidney transplant patients to the recommended lifestyle behaviours: single centre experience. Int J Nurs Pract; 2008 Oct;14(5):398-407
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compliance of kidney transplant patients to the recommended lifestyle behaviours: single centre experience.
  • Successful management of kidney transplant patients requires lifelong therapeutic regimen.
  • The aim of the study was to identify compliance of kidney transplant patients to the recommended lifestyle behaviours.
  • One hundred adult kidney transplant patients of 6 months duration and more participated in this study regardless of age or sex.
  • A structured questionnaire was developed which included socio-demographic characteristics, the recommended lifestyle behaviours of the kidney transplant patients and the kidney transplant patient's health condition and his results from the laboratory tests.
  • The nurse must provide the kidney transplant patients with the necessary knowledge of the recommended lifestyle behaviours.
  • [MeSH-major] Kidney Transplantation. Life Style. Patient Compliance

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18808541.001).
  • [ISSN] 1440-172X
  • [Journal-full-title] International journal of nursing practice
  • [ISO-abbreviation] Int J Nurs Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


57. Briet M, Schiffrin EL: Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol; 2010 May;6(5):261-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aldosterone: effects on the kidney and cardiovascular system.
  • Aldosterone, a steroid hormone with mineralocorticoid activity, is mainly recognized for its action on sodium reabsorption in the distal nephron of the kidney, which is mediated by the epithelial sodium channel (ENaC).
  • Beyond this well-known action, however, aldosterone exerts other effects on the kidney, blood vessels and the heart, which can have pathophysiological consequences, particularly in the presence of a high salt intake.
  • Aldosterone is implicated in renal inflammatory and fibrotic processes, as well as in podocyte injury and mesangial cell proliferation.
  • Small interventional studies in patients with chronic kidney disease have shown promising results, with a significant reduction of proteinuria associated with aldosterone antagonism, but large interventional trials that test the efficacy and safety of mineralocorticoid-receptor antagonists in chronic kidney disease are needed.
  • [MeSH-major] Aldosterone / adverse effects. Aldosterone / pharmacology. Angiotensin II Type 1 Receptor Blockers / pharmacology. Cardiovascular Diseases / chemically induced. Cardiovascular Diseases / drug therapy. Cardiovascular System / drug effects. Kidney / drug effects. Mineralocorticoid Receptor Antagonists / pharmacology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20234356.001).
  • [ISSN] 1759-507X
  • [Journal-full-title] Nature reviews. Nephrology
  • [ISO-abbreviation] Nat Rev Nephrol
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / / 37917; Canada / Canadian Institutes of Health Research / / 82790
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Mineralocorticoid Receptor Antagonists; 0 / Sodium Channels; 0 / Sodium, Dietary; 4964P6T9RB / Aldosterone
  • [Number-of-references] 141
  •  go-up   go-down


58. Ashrith G, Elayda MA, Wilson JM: Revascularization options in patients with chronic kidney disease. Tex Heart Inst J; 2010;37(1):9-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revascularization options in patients with chronic kidney disease.
  • Cardiovascular disease is the leading cause of death in patients who have chronic kidney disease or end-stage renal disease and are undergoing hemodialysis.
  • Chronic kidney disease is a recognized risk factor for premature atherosclerosis.
  • Unfortunately, most major randomized clinical trials that form the basis for evidence-based use of revascularization procedures exclude patients who have renal insufficiency.
  • Retrospective, observational studies suggest that patients with end-stage renal disease and severe coronary occlusive disease have a lower risk of death if they undergo coronary revascularization rather than medical therapy alone.
  • This difference appears to result from poor long-term results of percutaneous coronary intervention in patients who have chronic kidney disease or end-stage renal disease.Because randomized trials comparing percutaneous coronary intervention and coronary artery bypass grafting have included patients undergoing balloon angioplasty and placement of bare-metal stents, their conclusions are suspect in the era of drug-eluting stents.
  • In this review, we discuss different revascularization options for patients with chronic kidney disease, the outcomes of revascularization procedures, and the risk factors for adverse outcomes.

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2005 Aug;128(2):855-62 [16100178.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Sep;130(3):746-52 [16153923.001]
  • [Cites] Circulation. 2005 Aug 30;112(9 Suppl):I270-5 [16159830.001]
  • [Cites] J Interv Cardiol. 2005 Oct;18(5):331-7 [16202107.001]
  • [Cites] Ann Thorac Surg. 2005 Dec;80(6):2148-53 [16305860.001]
  • [Cites] Am Heart J. 2005 Dec;150(6):1163-70 [16338253.001]
  • [Cites] Ann Thorac Surg. 2006 Feb;81(2):591-8; discussion 598 [16427858.001]
  • [Cites] Circulation. 2006 Feb 28;113(8):1063-70 [16490821.001]
  • [Cites] Kidney Blood Press Res. 2005;28(5-6):270-4 [16534220.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Apr;29(4):461-5 [16483789.001]
  • [Cites] J Am Soc Nephrol. 2006 Apr;17(4):1175-80 [16481413.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Jun;131(6):1261-6 [16733155.001]
  • [Cites] J Invasive Cardiol. 2006 Jun;18(6):273-7 [16751681.001]
  • [Cites] Kidney Int. 2006 Aug;70(4):757-64 [16788687.001]
  • [Cites] J Invasive Cardiol. 2006 Sep;18(9):405-8 [16954577.001]
  • [Cites] J Invasive Cardiol. 2006 Sep;18(9):409-10 [16954578.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2006 Aug;12(4):257-64 [16977295.001]
  • [Cites] J Invasive Cardiol. 2006 Dec;18(12):577-83 [17197706.001]
  • [Cites] Circulation. 2007 Jul 17;116(3):298-304 [17606842.001]
  • [Cites] J Invasive Cardiol. 2007 Aug;19(8):331-7 [17712200.001]
  • [Cites] Clin Transplant. 2007 Sep-Oct;21(5):609-14 [17845634.001]
  • [Cites] JAMA. 2007 Nov 7;298(17):2038-47 [17986697.001]
  • [Cites] Am J Kidney Dis. 2008 Jan;51(1 Suppl 1):S1-320 [18086389.001]
  • [Cites] J Am Coll Cardiol. 2008 May 27;51(21):2017-24 [18498954.001]
  • [Cites] Ann Thorac Surg. 1999 Oct;68(4):1257-61 [10543489.001]
  • [Cites] Kidney Int. 2000 Jan;57(1):307-13 [10620213.001]
  • [Cites] Cardiol Rev. 2008 Jul-Aug;16(4):213-8 [18562812.001]
  • [Cites] Circulation. 2008 Oct 28;118(18):1817-27 [18852368.001]
  • [Cites] Circulation. 2008 Nov 18;118(21):2130-8 [18981306.001]
  • [Cites] Artif Organs. 2001 Apr;25(4):239-47 [11318749.001]
  • [Cites] Artif Organs. 2001 Apr;25(4):268-72 [11318755.001]
  • [Cites] Ital Heart J. 2001 May;2(5):379-83 [11392643.001]
  • [Cites] Kidney Int. 2001 Jul;60(1):292-9 [11422764.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2001 Nov;49(11):660-5 [11757338.001]
  • [Cites] Circulation. 2004 Jun 15;109(23):2866-71 [15159290.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Jan;15(1):51-4 [10077373.001]
  • [Cites] Artif Organs. 2003 Feb;27(2):174-80 [12580775.001]
  • [Cites] Am J Cardiol. 2000 Jun 1;85(11):1365-8 [10831956.001]
  • [Cites] Am J Cardiol. 2000 Aug 15;86(4):395-9 [10946031.001]
  • [Cites] Am J Cardiol. 2000 Sep 1;86(5):485-9 [11009262.001]
  • [Cites] Ann Thorac Surg. 2000 Sep;70(3):813-8; discussion 819 [11016315.001]
  • [Cites] Circulation. 2000 Dec 12;102(24):2973-7 [11113048.001]
  • [Cites] Ann Thorac Surg. 2001 Feb;71(2):543-8 [11235703.001]
  • [Cites] Heart. 2001 May;85(5):556-60 [11303010.001]
  • [Cites] Am J Nephrol. 1999;19(1):38-44 [10085448.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 May;15(5):691-6 [10386419.001]
  • [Cites] Kidney Int. 1999 Jul;56(1):324-32 [10411709.001]
  • [Cites] Ann Thorac Surg. 2004 Dec;78(6):2044-9 [15561032.001]
  • [Cites] Am J Cardiol. 2005 Jan 15;95(2):167-72 [15642546.001]
  • [Cites] Scand J Urol Nephrol. 2004;38(5):405-16 [15764253.001]
  • [Cites] Ann Thorac Surg. 2005 May;79(5):1577-83 [15854936.001]
  • [Cites] Circulation. 2005 May 31;111(21):2858-64 [15927994.001]
  • [Cites] Eur Heart J. 2005 Aug;26(15):1488-93 [15860519.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2001 Dec;49(12):693-9 [11808090.001]
  • [Cites] J Am Coll Cardiol. 2002 Apr 3;39(7):1113-9 [11923033.001]
  • [Cites] Int Urol Nephrol. 2001;32(4):717-23 [11989572.001]
  • [Cites] Circulation. 2002 May 14;105(19):2253-8 [12010906.001]
  • [Cites] Circulation. 2002 Oct 22;106(17):2207-11 [12390949.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):496-500 [12607660.001]
  • [Cites] Kidney Int. 2003 Mar;63(3):1121-9 [12631096.001]
  • [Cites] Circulation. 2003 Jun 3;107(21):2653-5 [12756161.001]
  • [Cites] J Am Soc Nephrol. 2003 Sep;14(9):2373-80 [12937316.001]
  • [Cites] Am J Cardiol. 2003 Sep 15;92(6):721-5 [12972118.001]
  • [Cites] J Am Soc Nephrol. 2003 Oct;14(10):2556-72 [14514733.001]
  • [Cites] J Am Soc Nephrol. 2004 Mar;15(3):517-23 [14978153.001]
  • [Cites] Kidney Int. 2004 Jul;66(1):441-7 [15200454.001]
  • [Cites] Am J Cardiol. 2004 Jul 1;94(1):30-4 [15219504.001]
  • [Cites] Am J Kidney Dis. 2004 Oct;44(4):627-35 [15384013.001]
  • [Cites] J Card Surg. 2004 Sep-Oct;19(5):449-52 [15383059.001]
  • [Cites] Am Heart J. 2004 Sep;148(3):430-8 [15389229.001]
  • [Cites] Mayo Clin Proc. 1991 Jan;66(1):45-53 [1988758.001]
  • [Cites] Am J Kidney Dis. 1995 Feb;25(2):281-90 [7847356.001]
  • [Cites] Ann Thorac Surg. 1996 Jun;61(6):1793-6 [8651786.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):217-25 [8657237.001]
  • [Cites] Heart. 1997 Oct;78(4):337-42 [9404246.001]
  • [Cites] Cardiovasc Surg. 1998 Oct;6(5):500-5 [9794271.001]
  • (PMID = 20200622.001).
  • [ISSN] 1526-6702
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  • [Other-IDs] NLM/ PMC2829816
  • [Keywords] NOTNLM ; Angioplasty, transluminal, percutanous coronary / coronary artery bypass / coronary artery bypass, off-pump / creatinine/blood/metabolism / drug-eluting stents / extracorporeal circulation / glomerular filtration rate / kidney failure, chronic / renal dialysis / stents / treatment outcome
  •  go-up   go-down


59. Parzanese I, Maccarone D, Caniglia L, Pisani F, Mazzotta C, Rizza V, Famulari A: Risk factors that can influence kidney transplant outcome. Transplant Proc; 2006 May;38(4):1022-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors that can influence kidney transplant outcome.
  • The survival and function of a kidney transplant are influenced by numerous immunological and nonimmunological factors.
  • The aim of this study was to evaluate the role of a number of cadaveric donor parameters on transplanted kidney function, and in particular on the occurrence of delayed graft function (DGF) since DGF is one of the most important factors in long-term organ survival.
  • This study looked at 143 patients who underwent kidney transplant of whom 32 displayed DGF.
  • We observed that a donor history of hypertension (46.8% DGF vs 23.27% no DGF; P = .01) and high levels of donor creatinine prior to organ removal (1.9 +/- 1.2 mg/dL DGF vs 1.2 +/- 0.9 mg/dL no DGF; P = .007) were significant risk factors for DGF among kidney recipients.
  • [MeSH-major] Delayed Graft Function / physiopathology. Graft Survival / physiology. Kidney Transplantation / adverse effects. Kidney Transplantation / physiology
  • [MeSH-minor] Cadaver. Creatinine / blood. Follow-Up Studies. Humans. Kidney Function Tests. Retrospective Studies. Risk Factors. Time Factors. Tissue Donors / statistics & numerical data. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16757251.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


60. Campese VM, Hadaya B, Chiu J: HMG-CoA reductase inhibitors and the kidney. Curr Hypertens Rep; 2005 Oct;7(5):337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HMG-CoA reductase inhibitors and the kidney.
  • It has not been well established whether statins confer similar benefits to the kidney.
  • In this review, we critically consider the available data whereby dyslipidemia mediates renal dysfunction by modulating the inflammatory response to diverse cytokines.
  • We also review the emerging database suggesting that statins may modulate renal dysfunction by altering the response of the kidney to dyslipidemia, particularly in patients with end-stage renal disease (ESRD) and post-kidney transplant.
  • [MeSH-major] Cardiovascular Diseases / prevention & control. Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use. Kidney Diseases / therapy
  • [MeSH-minor] Dyslipidemias / complications. Dyslipidemias / drug therapy. Humans. Inflammation / drug therapy. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / therapy. Kidney Transplantation

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 1996 May 27;61(10):1469-74 [8633373.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Jan 1;23 (1):58-63 [12524225.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1452-8 [12231565.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):729-36 [12615672.001]
  • [Cites] Circulation. 1997 Mar 4;95(5):1126-31 [9054840.001]
  • [Cites] J Clin Invest. 1998 Jun 15;101(12):2711-9 [9637705.001]
  • [Cites] Transplantation. 1994 Jan;57(1):68-72 [8291116.001]
  • [Cites] Atherosclerosis. 2002 Jan;160(1):141-6 [11755931.001]
  • [Cites] J Hypertens. 2002 Dec;20(12):2465-73 [12473872.001]
  • [Cites] BMC Cardiovasc Disord. 2003 Jul 19;3:6 [12871602.001]
  • [Cites] JAMA. 2004 Mar 3;291(9):1071-80 [14996776.001]
  • [Cites] Ann Intern Med. 2003 Oct 21;139(8):670-82 [14568856.001]
  • [Cites] Kidney Int Suppl. 1999 Jul;71:S10-3 [10412727.001]
  • [Cites] N Engl J Med. 1997 Aug 7;337(6):408-16 [9241131.001]
  • [Cites] Kidney Int. 1993 Apr;43(4):918-27 [8479130.001]
  • [Cites] Hypertension. 1995 Oct;26(4):670-5 [7558229.001]
  • [Cites] N Engl J Med. 2001 Nov 8;345(19):1419-21 [11794177.001]
  • [Cites] Nephron. 2002 Apr;90(4):373-8 [11961394.001]
  • [Cites] Kidney Int Suppl. 1999 Jul;71:S84-7 [10412745.001]
  • [Cites] J Nephrol. 2003 Mar-Apr;16(2):238-44 [12768071.001]
  • [Cites] J Am Soc Nephrol. 1993 Aug;4(2):187-94 [8400082.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):728-34 [15220366.001]
  • [Cites] N Engl J Med. 2004 Sep 23;351(13):1285-95 [15385655.001]
  • [Cites] Transplantation. 2001 Jul 27;72(2):223-7 [11477342.001]
  • [Cites] Kidney Int. 1993 Jan;43(1):218-25 [8433562.001]
  • [Cites] Circulation. 1998 Sep 1;98(9):839-44 [9738637.001]
  • [Cites] Pharmacol Res. 2002 Feb;45(2):147-54 [11846628.001]
  • [Cites] Circulation. 1998 Mar 31;97(12):1129-35 [9537338.001]
  • [Cites] J Am Soc Nephrol. 2003 Aug;14(8):2084-91 [12874462.001]
  • [Cites] Am J Kidney Dis. 2003 Apr;41(4 Suppl 3):I-IV, S1-91 [12671933.001]
  • [Cites] Free Radic Biol Med. 2002 Oct 15;33(8):1026-36 [12374614.001]
  • [Cites] Am J Kidney Dis. 2002 Jun;39(6):1213-7 [12046033.001]
  • [Cites] Kidney Int. 2002 Jan;61(1):297-304 [11786112.001]
  • [Cites] Am J Kidney Dis. 2003 Mar;41(3):565-70 [12612979.001]
  • [Cites] Kidney Int. 1997 Oct;52(4):1016-27 [9328940.001]
  • [Cites] J Biol Chem. 1991 Jul 5;266(19):12216-22 [1712015.001]
  • [Cites] Kidney Int. 2002 Nov;62(5):1524-38 [12371953.001]
  • [Cites] N Engl J Med. 2004 Sep 23;351(13):1296-305 [15385656.001]
  • [Cites] Nephrol Dial Transplant. 2002 Mar;17(3):347-8 [11865072.001]
  • [Cites] Am J Kidney Dis. 1998 Jan;31(1):190-4 [9428473.001]
  • [Cites] Circulation. 2001 Apr 17;103(15):1933-5 [11306519.001]
  • [Cites] Circulation. 1999 Jul 20;100(3):230-5 [10411845.001]
  • [Cites] J Am Soc Nephrol. 2003 Jun;14(6):1605-13 [12761262.001]
  • [Cites] Clin Sci (Lond). 2003 Sep;105(3):251-66 [12793855.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10 ):621-7 [7637722.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1165-71 [11451746.001]
  • [Cites] Atherosclerosis. 1999 Dec;147(2):253-61 [10559511.001]
  • [Cites] Kidney Int. 2001 Jan;59(1):260-9 [11135079.001]
  • (PMID = 16157074.001).
  • [ISSN] 1522-6417
  • [Journal-full-title] Current hypertension reports
  • [ISO-abbreviation] Curr. Hypertens. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • [Number-of-references] 50
  •  go-up   go-down


61. Harel Z, Perl J, Herzenberg AM, Bargman JM: Inflammatory pseudotumor of the kidney allograft. Am J Kidney Dis; 2009 Sep;54(3):533-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory pseudotumor of the kidney allograft.
  • Inflammatory myofibroblastic tumor, or inflammatory pseudotumor, usually is a benign lesion composed of mixed inflammatory and fibroblastic elements.
  • It has rarely been reported in the posttransplantation setting and never in association with a renal allograft.
  • We report the first case of inflammatory myofibroblastic tumor infiltrating a renal allograft and highlight the role immunosuppression may have in the development of this lesion.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Granuloma, Plasma Cell / pathology. Kidney Diseases / diagnosis. Kidney Diseases / pathology. Kidney Transplantation / adverse effects. Kidney Transplantation / pathology

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19376619.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Aregger F, Pilop C, Uehlinger DE, Brunisholz R, Carrel TP, Frey FJ, Frey BM: Urinary proteomics before and after extracorporeal circulation in patients with and without acute kidney injury. J Thorac Cardiovasc Surg; 2010 Mar;139(3):692-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary proteomics before and after extracorporeal circulation in patients with and without acute kidney injury.
  • OBJECTIVE: Acute kidney injury is a well-known complication with high morbidity and mortality after cardiopulmonary bypass.
  • Cardiopulmonary bypass-associated acute kidney injury is still poorly understood.
  • Acute kidney injury was defined according to the RIFLE classification.
  • To identify differentially regulated proteins in acute kidney injury, we next compared the urinary proteome obtained on the first postoperative day between patients with and without acute kidney injury.
  • Acute kidney injury developed in 6 of 36 patients.
  • A modified urinary albumin was increased, and zinc-alpha-2-glycoprotein and a fragment of adrenomedullin-binding protein were decreased in patients with acute kidney injury.
  • Decreased excretion of zinc-alpha-2-glycoprotein in patients with acute kidney injury was confirmed by Western blot and enzyme-linked immunosorbent assay in an independent cohort of 22 patients with and 46 patients without acute kidney injury.
  • Zinc-alpha-2-glycoprotein is a potentially useful predictive marker for acute kidney injury after cardiopulmonary bypass surgery.
  • [MeSH-major] Cardiopulmonary Bypass / adverse effects. Kidney Diseases / etiology. Kidney Diseases / urine. Proteomics

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20176211.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Bhosale P, Peungjesada S, Devine C, Balachandran A, Iyer R: Role of magnetic resonance imaging as an adjunct to clinical staging in cervical carcinoma. J Comput Assist Tomogr; 2010 Nov-Dec;34(6):855-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging depicts the morphological details of the female pelvis and is useful for evaluating both benign and malignant cervical masses.
  • Clinical staging, as defined by FIGO (International Federation of Gynecologic Oncology), is based on the findings of physical examination, lesion biopsies, chest radiography, cystoscopy, and renal sonography and can be erroneous, depending on the stage of the disease, by 16% to 65%.
  • The prognosis of cervical cancer is determined not only by stage, but also by nodal status, tumor volume, and depth of invasion, none of which are included in the FIGO guidelines.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Contrast Media. Female. Humans. Lymphatic Metastasis / pathology. Neoplasm Staging. Sensitivity and Specificity


64. Can B, Kulaksiz Erkmen G, Dalmizrak O, Ogus IH, Ozer N: Purification and characterisation of rat kidney glutathione reductase. Protein J; 2010 May;29(4):250-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purification and characterisation of rat kidney glutathione reductase.
  • Kidney and liver tissues were considered as a rich source of GR.
  • In this study, rat kidney GR was purified and some of its properties were investigated.
  • NADH was used as a coenzyme by rat kidney GR but with a lower efficiency (32.7%) than NADPH.
  • An optimum pH of 6.5 and optimum temperature of 65 degrees C were found for rat kidney GR.
  • [MeSH-major] Glutathione Reductase / chemistry. Glutathione Reductase / metabolism. Kidney / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biochem. 2007 Mar;297(1-2):139-49 [17075686.001]
  • [Cites] Anal Biochem. 1981 Sep 15;116(2):531-6 [7316181.001]
  • [Cites] J Bacteriol. 1984 Apr;158(1):317-24 [6425264.001]
  • [Cites] J Nutr. 2004 Mar;134(3):489-92 [14988435.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Biochem J. 1987 Aug 1;245(3):875-80 [3311037.001]
  • [Cites] Biochemistry. 1990 Jun 19;29(24):5790-6 [2200516.001]
  • [Cites] Science. 1983 Apr 29;220(4596):472-7 [6836290.001]
  • [Cites] J Biol Chem. 1986 Feb 5;261(4):1629-35 [3003077.001]
  • [Cites] Eur J Biochem. 1996 Jan 15;235(1-2):345-50 [8631352.001]
  • [Cites] Biochemistry. 1982 Dec 21;21(26):6628-33 [7159551.001]
  • [Cites] J Exp Bot. 2002 May;53(372):1283-304 [11997376.001]
  • [Cites] FEBS Lett. 1989 Jun 19;250(1):72-4 [2737302.001]
  • [Cites] Blood. 1963 May;21:573-85 [13967896.001]
  • [Cites] Protist. 2010 Jan;161(1):91-101 [19664954.001]
  • [Cites] Eur J Biochem. 1979 Aug 1;98(2):487-99 [39757.001]
  • [Cites] J Biol Chem. 1975 Jul 25;250(14):5475-80 [237922.001]
  • [Cites] J Biol Chem. 1968 Feb 25;243(4):809-14 [5638597.001]
  • [Cites] J Biol Chem. 1952 Jan;194(1):119-30 [14927599.001]
  • [Cites] Protein Pept Lett. 2010 May;17(5):667-74 [19702563.001]
  • [Cites] Methods Enzymol. 1985;113:484-90 [3003504.001]
  • [Cites] EMBO Rep. 2006 Mar;7(3):271-5 [16607396.001]
  • [Cites] Biochem J. 1987 Mar 1;242(2):511-5 [3109393.001]
  • [Cites] Enzyme. 1991;45(3):121-4 [1815946.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Pathol Biol (Paris). 1996 Jan;44(1):77-85 [8734304.001]
  • [Cites] Brain Res. 1995 May 22;680(1-2):16-22 [7663973.001]
  • [Cites] Protein Expr Purif. 1998 Jun;13(1):41-4 [9631513.001]
  • [Cites] Biochem Med Metab Biol. 1991 Feb;45(1):65-73 [2015111.001]
  • [Cites] Protein J. 2004 Jul;23(5):317-24 [15328887.001]
  • [Cites] Plant Physiol. 1992 Sep;100(1):138-45 [16652936.001]
  • (PMID = 20490902.001).
  • [ISSN] 1875-8355
  • [Journal-full-title] The protein journal
  • [ISO-abbreviation] Protein J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 53-59-8 / NADP; EC 1.8.1.7 / Glutathione Reductase; ULW86O013H / Glutathione Disulfide
  •  go-up   go-down


65. Leclerc E, Baudoin R, Corlu A, Griscom L, Luc Duval J, Legallais C: Selective control of liver and kidney cells migration during organotypic cocultures inside fibronectin-coated rectangular silicone microchannels. Biomaterials; 2007 Apr;28(10):1820-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective control of liver and kidney cells migration during organotypic cocultures inside fibronectin-coated rectangular silicone microchannels.
  • In this work, the behaviors of embryonic liver and kidney explants were studied inside rectangular polydimethylsiloxane (PDMS) microchannels.
  • In kidney monocultures, with and without fibronectin, we did not observe any migration inside the microchannels.
  • Contrary to liver cells, kidney cell migration was triggered when both fibronectin coating and coculture with liver or another kidney explant were used.
  • The migration was more largely observed in coculture with liver when compared to kidney-kidney cocultures.
  • In the case of liver-kidney coculture with fibronectin, the progression of the kidney cells inside the microchannels appears as a displacement of the entire kidney explant in the direction of the liver.
  • After contact, we observed a complete merging of both liver and kidney explants.
  • In contrast, for liver-kidney cocultures without fibronectin, only the liver moved toward the kidney.
  • [MeSH-major] Fibronectins / pharmacology. Kidney / cytology. Liver / cytology. Liver / growth & development. Liver, Artificial. Organ Culture Techniques / instrumentation. Tissue Engineering / instrumentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178157.001).
  • [ISSN] 0142-9612
  • [Journal-full-title] Biomaterials
  • [ISO-abbreviation] Biomaterials
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coated Materials, Biocompatible; 0 / Fibronectins; 0 / Silicones
  •  go-up   go-down


66. Santiago C, Lucha PA: Atypical presentation of a retrorectal ancient schwannoma: a case report and review of the literature. Mil Med; 2008 Aug;173(8):814-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retrorectal tumors are rare and frequently present either incidentally or with vague symptoms.
  • Schwannomas of the presacral region are one variant described as benign tumors of neurogenic origin.
  • We present the case of a 37-year-old man presenting with symptoms of left renal colic, impotence, and left trochanteric pain.
  • The patient underwent an exploratory laparotomy with resection of the tumor, which subsequent analysis showed to be a schwannoma with ancient degenerative changes.
  • [MeSH-major] Neurilemmoma / diagnosis. Rectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751604.001).
  • [ISSN] 0026-4075
  • [Journal-full-title] Military medicine
  • [ISO-abbreviation] Mil Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 15
  •  go-up   go-down


67. Anchi T, Tamura K, Inoue K, Ashida S, Yamasaki I, Takeuchi T, Shuin T: [A case of carcinoid tumor arising from a horseshoe kidney]. Hinyokika Kiyo; 2009 Jun;55(6):327-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of carcinoid tumor arising from a horseshoe kidney].
  • Carcinoid tumor of the kidney is an extremely rare neoplasm.
  • We report a case of primary carcinoid tumor arising from a horseshoe kidney in a 31-year-old man.
  • From the results of computed tomography, magnetic resonance imaging and angiography, we suspected renal tumor arising from a horseshoe kidney and performed left partial nephrectomy with isthmectomy.
  • Pathological findings of hematoxylin eosin staining revealed tumor cells proliferating in a cord-like and ribbon-like structure and the tumor cells stained strongly for chromogranin A, grimelius and neuron specific enolase.
  • According to these findings, we diagnosed carcinoid tumor arising from a horseshoe kidney.
  • [MeSH-major] Carcinoid Tumor / etiology. Kidney / abnormalities. Kidney Neoplasms / etiology


68. Astigueta JC, Abad MA, Pow-Sang MR, Morante C, Meza L, Destefano V, Dyer R: Epithelioid angiomyolipoma: a rare variant of renal angiomyolipoma. Arch Esp Urol; 2009 Jul;62(6):493-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid angiomyolipoma: a rare variant of renal angiomyolipoma.
  • OBJECTIVE: We present a case of primary renal epithelioid angiomyolipoma, its association with tuberous sclerosis and review the literature.
  • CT scan of the abdomen showed the presence of a left renal tumor.
  • Pathologic study of the specimen showed primary renal epithelioid angiomyolipoma, corroborated by immunohistochemistry staining.
  • CONCLUSIONS: Renal angiomyolipoma is an uncommon benign tumor, representing a challenge for clinical and pathological diagnosis.
  • [MeSH-major] Angiomyolipoma / pathology. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736381.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 15
  •  go-up   go-down


69. Crane HM, Kestenbaum B, Harrington RD, Kitahata MM: Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS; 2007 Jul 11;21(11):1431-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
  • OBJECTIVE: To examine the effect of antiretroviral agents and clinical factors on the development of tenofovir-associated kidney dysfunction.
  • Patients' kidney function prior to initiating and while receiving tenofovir was evaluated in relation to other antiretroviral medications and demographic and clinical characteristics.
  • Decline in kidney function was assessed by the glomerular filtration rate (GFR) as estimated by the Cockcroft-Gault (CG) equation, which incorporates weight.
  • Secondary analyses used the simplified Modification of Diet in Renal Disease (MDRD) equation.
  • RESULTS: Among the 445 patients initiating tenofovir, 51 (11%) developed a decline in kidney function.
  • In multivariate analysis, there was a significant association between decline in kidney function and concurrent use of amprenavir [odds ratio (OR) 3.6; P = 0.045] and didanosine (OR, 3.1; P = 0.006), age over 50 years (OR, 4.4; P = 0.03), and lower baseline weight (OR, 0.95/kg; P < 0.001).
  • Patients identified with kidney dysfunction by the MDRD equation did not fully overlap with those identified by the CG equation.
  • CONCLUSIONS: Didanosine and amprenavir use, increased age, and lower baseline weight were significantly associated with risk for kidney dysfunction among patients receiving tenofovir.
  • [MeSH-minor] Adult. Age Factors. Analysis of Variance. Antiretroviral Therapy, Highly Active. Body Weight. Carbamates / adverse effects. Carbamates / therapeutic use. Creatinine / urine. Didanosine / adverse effects. Didanosine / therapeutic use. Drug Interactions. Female. Glomerular Filtration Rate / drug effects. Humans. Kidney / drug effects. Kidney / metabolism. Linear Models. Male. Middle Aged. Sulfonamides / adverse effects. Sulfonamides / therapeutic use. Tenofovir. Time Factors

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Renal Manifestations of HIV .
  • Hazardous Substances Data Bank. AMPRENAVIR .
  • Hazardous Substances Data Bank. DIDEOXYINOSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AIDS. 2007 Nov 30;21(18):2566 [18025906.001]
  • (PMID = 17589189.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI-060464; United States / NIAID NIH HHS / AI / AI-27757
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Carbamates; 0 / Organophosphonates; 0 / Sulfonamides; 5S0W860XNR / amprenavir; 99YXE507IL / Tenofovir; AYI8EX34EU / Creatinine; JAC85A2161 / Adenine; K3GDH6OH08 / Didanosine
  •  go-up   go-down


70. Montgomery RA, Zachary AA, Ratner LE, Segev DL, Hiller JM, Houp J, Cooper M, Kavoussi L, Jarrett T, Burdick J, Maley WR, Melancon JK, Kozlowski T, Simpkins CE, Phillips M, Desai A, Collins V, Reeb B, Kraus E, Rabb H, Leffell MS, Warren DS: Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA; 2005 Oct 5;294(13):1655-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation.
  • CONTEXT: First proposed 2 decades ago, live kidney paired donation (KPD) was considered a promising new approach to addressing the shortage of organs for transplantation.
  • DESIGN, SETTING, AND PATIENTS: Prospective series of paired donations matched and transplanted from a pool of blood type or crossmatch incompatible donors and recipients with end-stage renal disease (6 conventional and 4 unconventional KPD transplants) at a US tertiary referral center (between June 2001 and November 2004) with expertise in performing transplants in patients with high immunologic risk.
  • INTERVENTION: Kidney paired donation and live donor renal transplantation.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2005 Oct 5;294(13):1691-3 [16204670.001]
  • (PMID = 16204665.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Nakamura Y, Urashima M, Nishihara R, Matsuura A, Bekku K, Iguchi H, Uesugi T, Saegusa M, Aramaki K: Inflammatory pseudotumor of the kidney with renal artery penetration. Radiat Med; 2007 Dec;25(10):541-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory pseudotumor of the kidney with renal artery penetration.
  • Inflammatory pseudotumor (IPT) is a quasineoplastic lesion that most commonly involves the lung and the orbit; kidney involvement is rare.
  • We report a case of inflammatory pseudotumor of the kidney.
  • Nonenhanced computed tomography (CT) demonstrated an ill-defined, isodensity mass measuring 3.5 cm in the lower portion of the left kidney.
  • Contrast-enhanced CT showed that branches of the renal artery without encasement penetrated the tumor; there was a little enhancement in the mass on the arterial phase and homogeneous enhancement on the venous phase.
  • Most IPTs of the kidney appear as an ill-defined, hypovascular, homogeneous tumor on CT images, with variable signal intensity on MRI T1WIs and low signal intensity on T2WIs.
  • Our case had the same imaging findings, with branches of the renal artery penetrating the tumor.
  • If the renal tumor has these radiological findings, the tumor may be IPT.
  • [MeSH-major] Granuloma, Plasma Cell / pathology. Kidney Diseases / pathology. Renal Artery / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Esp Urol. 2002 Jan-Feb;55(1):85-7 [11957761.001]
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):478-80 [10834015.001]
  • [Cites] Int J Urol. 2004 May;11(5):337-9 [15147553.001]
  • [Cites] Actas Urol Esp. 2003 Oct;27(9):739-41 [14626687.001]
  • [Cites] Int Urol Nephrol. 2004;36(2):141-3 [15368680.001]
  • [Cites] Prog Urol. 2003 Feb;13(1):135-9 [12703371.001]
  • [Cites] Arch Esp Urol. 2003 May;56(4):428-30 [12830617.001]
  • [Cites] Am J Nephrol. 2000 May-Jun;20(3):217-21 [10878405.001]
  • [Cites] AJR Am J Roentgenol. 1996 May;166(5):1151-5 [8615260.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):658-66 [12717250.001]
  • [Cites] Int J Urol. 1999 Feb;6(2):107-10 [10226817.001]
  • [Cites] Am J Kidney Dis. 1998 Jun;31(6):E5 [10074585.001]
  • [Cites] J Urol. 1972 Jun;107(6):938-9 [5033977.001]
  • [Cites] J Thorac Surg. 1954 Jul;28(1):55-63 [13175281.001]
  • [Cites] Hinyokika Kiyo. 2004 Sep;50(9):629-31 [15518129.001]
  • [Cites] Hinyokika Kiyo. 2006 Jan;52(1):31-3 [16479987.001]
  • [Cites] South Med J. 1998 Nov;91(11):1050-3 [9824189.001]
  • [Cites] Br J Urol. 1990 May;65(5):548-9 [2354326.001]
  • [Cites] Verh Dtsch Ges Pathol. 1998;82:75-82 [10095420.001]
  • [Cites] AJR Am J Roentgenol. 1976 Jun;126(6):1197-1202 [179381.001]
  • [Cites] Bone Marrow Transplant. 2004 Nov;34(9):831-2 [15322569.001]
  • [Cites] Radiographics. 2003 May-Jun;23(3):719-29 [12740472.001]
  • [Cites] Rev Med Interne. 2000 Oct;21(10):889-92 [11075397.001]
  • [Cites] Ann Urol (Paris). 2001 Jan;35(1):30-3 [11233317.001]
  • [Cites] Radiology. 2005 Aug;236(2):441-50 [16040900.001]
  • [Cites] J Urol. 1982 Jun;127(6):1177-8 [7087029.001]
  • [Cites] Hinyokika Kiyo. 2000 Jan;46(1):23-6 [10723660.001]
  • [Cites] AJR Am J Roentgenol. 1990 Oct;155(4):713-22 [2119098.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2001 Jul;92(5):589-92 [11517572.001]
  • [Cites] Actas Urol Esp. 2005 Sep;29(8):794-6 [16304914.001]
  • [Cites] Urology. 1976 Jul;8(1):89-91 [941370.001]
  • [Cites] Surg Today. 2006;36(8):710-3 [16865515.001]
  • [Cites] Int Urol Nephrol. 2004;36(2):137-40 [15368679.001]
  • [Cites] Korean J Radiol. 2000 Oct-Dec;1(4):219-22 [11752959.001]
  • [Cites] Ann Urol (Paris). 2003 Aug;37(4):147-9 [12951701.001]
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1209-12 [10923085.001]
  • [Cites] Pediatr Pathol. 1992 Jul-Aug;12 (4):557-61 [1409154.001]
  • (PMID = 18085406.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


72. Arija I, Centeno C, Viveros A, Brenes A, Marzo F, Illera JC, Silvan G: Nutritional evaluation of raw and extruded kidney bean (Phaseolus vulgaris L. var. pinto) in chicken diets. Poult Sci; 2006 Apr;85(4):635-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutritional evaluation of raw and extruded kidney bean (Phaseolus vulgaris L. var. pinto) in chicken diets.
  • An experiment was conducted to study the effect of inclusion of different concentrations (0, 100, 200, and 300 g/kg) of raw kidney bean and extruded kidney bean in broiler chick (0 to 21 d of age) diets on performance, digestive organ sizes, protein and amino acid digestibilities, intestinal viscosity, cecal pH, and blood parameters.
  • Data were analyzed as a 3 x 2 factorial arrangement with 3 levels of kidney bean with and without extrusion.
  • Positive control without kidney bean was used.
  • Increasing the kidney bean content in the diet reduced weight gain and consumption, and increased the feed-to-gain ratio.
  • Relative pancreas, liver, and jejunum weights, and intestinal viscosity were increased in response to increasing kidney bean concentration in the diet.
  • The inclusion of different concentrations of kidney bean did not affect the apparent ileal digestibility of essential and nonessential amino acids, except for Met, Phe, and Cys, which were increased.
  • Increasing kidney bean in the diet did not affect blood parameters, except for total protein, which was increased, and for androstenedione and testosterone, which were reduced.
  • We concluded that the inclusion of kidney bean in chicken diets cause a negative effect on performance and CP and amino acid digestibilities, and modified digestive organ sizes, intestinal viscosity, cecal pH, and some blood parameters.
  • These effects were counteracted by the extrusion of kidney bean.
  • However, the inclusion of extruded kidney bean in a chick diet resulted in poorer performance compared with that obtained with a corn-soybean diet.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615347.001).
  • [ISSN] 0032-5791
  • [Journal-full-title] Poultry science
  • [ISO-abbreviation] Poult. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Plant Preparations
  •  go-up   go-down


73. Al-Bazzaz PH: Kidney transplantation in Erbil, Iraq: a single-center experience. Saudi J Kidney Dis Transpl; 2010 Mar;21(2):359-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney transplantation in Erbil, Iraq: a single-center experience.
  • Kidney transplantation is associated with improved quality of life and better survival among patients with end-stage renal disease.
  • The aim of this study is to assess the experience of kidney transplant program in a single center in Erbil, Iraq.
  • The records of 83 pairs, donors and recipients, treated with kidney transplantation at the Zheen Hospital in Erbil, over a two-year period were collected and analyzed.
  • In conclusion, even though experience related to kidney transplantation in Erbil is limited, the reported results are encouraging for a promising future.
  • [MeSH-major] Kidney Failure, Chronic / surgery. Kidney Transplantation. Tissue Donors / supply & distribution


74. Musquera Felip M, Peri Cusí L, Alcaraz Asensio A: [Surgical aspects of living-donor kidney transplantation]. Nefrologia; 2010;30 Suppl 2:71-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical aspects of living-donor kidney transplantation].
  • For these reasons, we can accept laparoscopic kidney living donor nephrectomy as the gold standard surgical technique in these patients.
  • In order to decide which kidney is better to extract, it is mandatory to maintain the best kidney in the donor.
  • [MeSH-major] Kidney Transplantation. Living Donors. Nephrectomy / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21183965.001).
  • [ISSN] 0211-6995
  • [Journal-full-title] Nefrología : publicación oficial de la Sociedad Española Nefrologia
  • [ISO-abbreviation] Nefrologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Spain
  •  go-up   go-down


75. Petrovic V, Jovanovic I, Pesic I, Stefanovic V: Role of stem cells in kidney repair. Ren Fail; 2010;32(10):1237-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of stem cells in kidney repair.
  • End-stage renal disease and acute renal failure are the most important issues of practical and clinical nephrology, bearing in mind their high mortality rate, solely symptomatic treatment, and overall economic impact on society.
  • The advances in stem cell biology opened the door for the new era in treatment of many disorders, including renal, offering new therapeutical solutions.
  • Findings suggesting that the adult kidney contains stem cells and that stem cells from bone marrow have potential to differentiate into renal cells focused research on the possible application of these cells in therapy of kidney disorders.
  • The other promising candidates for stem cell therapy for the kidney are embryonic stem cells and amniotic fluid-derived stem cells.
  • [MeSH-major] Kidney Failure, Chronic / surgery

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20954989.001).
  • [ISSN] 1525-6049
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


76. Qiao H, Bai J, Chen Y, Tian J: Kidney modelling for FDG excretion with PET. Int J Biomed Imaging; 2007;2007:63234
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney modelling for FDG excretion with PET.
  • The filtration process in kidney can be seen in the sequential images of each study.
  • Variational distribution of FDG in kidney can be detected in dynamic data.
  • According to the structure and function, kidney is divided into parenchyma and pelvis.
  • A unidirectional three-compartment model is proposed to describe the renal function in FDG excretion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 1999 Aug;40(8):1352-7 [10450688.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1358-66 [10450689.001]
  • [Cites] J Nucl Med. 2002 Oct;43(10):1331-8 [12368371.001]
  • [Cites] J Nucl Med. 2003 Jul;44(7):1113-47 [12843230.001]
  • [Cites] Am J Physiol. 1980 Jan;238(1):E69-82 [6965568.001]
  • (PMID = 17728841.001).
  • [ISSN] 1687-4188
  • [Journal-full-title] International journal of biomedical imaging
  • [ISO-abbreviation] Int J Biomed Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1950229
  •  go-up   go-down


77. Nemati E, Pourfarziani V, Jafari AM, Assari S, Moghani-Lankarani M, Khedmat H, Bagheri N, Saadat SH: Prediction of inpatient survival and graft loss in rehospitalized kidney recipients. Transplant Proc; 2007 May;39(4):974-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of inpatient survival and graft loss in rehospitalized kidney recipients.
  • INTRODUCTION: Despite a sizeable amount of research conducted hitherto into predictors of renal transplantation outcomes, there are scarce, data on predictors of in-hospital outcomes of post-kidney transplant rehospitalization.
  • This study sought to provide a user-friendly prediction model for inpatient mortality and graft loss among rehospitalized kidney recipients.
  • METHOD: This retrospective review of 424 consecutive kidney recipients rehospitalized after kidney transplantation between the years 2000 and 2005 used multiple logistic regression analysis to evaluate predictors of hospitalization outcomes.
  • RESULTS: Multivariate analysis showed that age at admission, diabetes mellitus as the cause of end-stage renal disease (ESRD), admission due to cerebrovascular accident (CVA), surgical complications were predictors of in-hospital death; age at transplantation, surgical complications, and rejection were predictors of graft loss.
  • CONCLUSIONS: Our prediction equations, using simple demographic and clinical variables, estimated the probability of inpatient mortality and graft loss among re-hospitalized kidney recipients.
  • [MeSH-major] Graft Survival / physiology. Hospital Mortality. Inpatients / statistics & numerical data. Kidney Transplantation / physiology. Patient Readmission / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524866.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Jeon HG, Lee SR, Kim KH, Oh YT, Cho NH, Rha KH, Yang SC, Han WK: Benign lesions after partial nephrectomy for presumed renal cell carcinoma in masses 4 cm or less: prevalence and predictors in Korean patients. Urology; 2010 Sep;76(3):574-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign lesions after partial nephrectomy for presumed renal cell carcinoma in masses 4 cm or less: prevalence and predictors in Korean patients.
  • OBJECTIVES: To investigate the prevalence and predictors associated with benign lesions in Korean patients after partial nephrectomy for presumed renal cell carcinoma (RCC) for lesions measuring ≤ 4 cm.
  • METHODS: We retrospectively investigated the medical records of 376 patients who underwent partial nephrectomy for presumed RCC with renal masses of size ≤ 4 cm between June 1997 and December 2008.
  • Demographic and clinicopathologic parameters were compared between benign lesions and RCC.
  • Logistic regression was done to identify parameters associated with benign lesions.
  • RESULTS: In the 376 patients, 81 tumors (21.5%) were benign, including 35 angiomyolipomas (9.3%), 26 complicated cysts (6.9%), 11 oncocytomas (2.9%), and 9 others (2.4%).
  • Univariate analysis showed that time of surgery, female sex, younger age, and normal body mass index (body mass index (BMI) < 23 kg/m(2)) were associated with benign pathologic findings.
  • On multiple logistic regression analysis, female sex (OR, 4.91; 95% CI, 2.76-08.75; P < .001), age (OR, 0.97; 95% CI, 0.95-0.99; P = .009), and time of surgery (OR, 0.33; 95% CI, 0.11-0.95; P = .040) were independent predictors of benign histologic features.
  • Tumor size, incidental diagnosis, and BMI were not significant predictors (P > .05).
  • CONCLUSIONS: Our study with a large cohort of Asian patients showed that the prevalence of benign lesions was similar to previously reported Western studies.
  • However, the most common benign lesion was angiomyolipoma, compared with oncocytoma in Western countries.
  • The results of this study may help clinicians counsel female and younger patients recently diagnosed with small renal masses and decide the most appropriate treatment, including renal biopsies and close observation.
  • [MeSH-major] Carcinoma, Renal Cell / epidemiology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / epidemiology. Kidney Neoplasms / pathology. Nephrectomy


79. Zhang X, Li HZ, Ma X, Zheng T, Li LC, Ye ZQ: Retroperitoneal laparoscopic nephron-sparing surgery for renal tumors: report of 32 cases. Urology; 2005 Jun;65(6):1080-4; discussion 1084-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal laparoscopic nephron-sparing surgery for renal tumors: report of 32 cases.
  • OBJECTIVES: To evaluate the feasibility and clinical efficacy of retroperitoneal laparoscopic nephron-sparing surgery for renal tumors.
  • METHODS: Between June 2002 and February 2004, 11 cases of renal benign tumor and 21 cases of renal malignant tumor underwent enucleation of the tumor and wedge resection of the tumor through retroperitoneal laparoscopy, respectively.
  • Tumor resection and hemostasis were mainly achieved by harmonic scalpel.
  • Follow-up studies were performed with an evaluation using renal spiral computed tomography.
  • The pathologic examination confirmed renal cell carcinoma in 21 patients and angiomyolipoma in 11.
  • The pathologic stage was pT1a in the 21 patients with renal cell carcinoma.
  • All resected tumor specimens had negative surgical margins for cancer.
  • CONCLUSIONS: Our results indicate that retroperitoneal laparoscopic nephron-sparing surgery represents a feasible option for patients with localized renal tumors.
  • This procedure could offer precise and complete tumor excision while minimizing morbidity, improving cosmesis, and shortening convalescence.
  • [MeSH-major] Kidney Neoplasms / surgery. Laparoscopy. Nephrectomy / methods
  • [MeSH-minor] Adult. Angiomyolipoma / surgery. Carcinoma, Renal Cell / surgery. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913730.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Hilhorst MT, Kranenburg LW, Busschbach JJ: Should health care professionals encourage living kidney donation? Med Health Care Philos; 2007 Mar;10(1):81-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should health care professionals encourage living kidney donation?
  • Living kidney donation provides a promising opportunity in situations where the scarcity of cadaveric kidneys is widely acknowledged.
  • While many patients and their relatives are willing to accept its benefits, others are concerned about living kidney programs; they appear to feel pressured into accepting living kidney transplantations as the only proper option for them.
  • Evidence suggests that both patients and their relatives have attitudes towards living kidney donation that are often open to change and, accordingly, can be influenced.
  • [MeSH-major] Counseling / ethics. Kidney Transplantation / psychology. Living Donors / psychology. Physician-Patient Relations / ethics. Professional-Family Relations / ethics


81. Lin SY, Liu WY, Chen WC, Chen RH: Secondary hypertension due to a renin-secreting juxtaglomerular cell tumor. J Formos Med Assoc; 2010 Mar;109(3):237-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary hypertension due to a renin-secreting juxtaglomerular cell tumor.
  • A juxtaglomerular cell tumor (JCT) is a rare, renin-secreting tumor of the kidney and can cause hypertension.
  • JCT is pathologically benign, and resection of the tumor is curative for hypertension.
  • Abdominal computed tomography disclosed a 2 cm solid mass in the left kidney.
  • However, renal vein sampling and captopril test results were equivocal.

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Formosan Medical Association & Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20434032.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] EC 3.4.23.15 / Renin
  •  go-up   go-down


82. Kageyama S, Tsuru T, Okamoto K, Narita M, Okada Y: Primary synovial sarcoma arising from a crossed ectopic kidney with fusion. Int J Urol; 2010 Jan;17(1):96-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary synovial sarcoma arising from a crossed ectopic kidney with fusion.
  • Crossed renal ectopia with fusion is a rare anomaly of the kidney.
  • The present case report describes a 67-year-old man with renal tumor who had been diagnosed as having a crossed ectopic kidney with fusion for 25 years.
  • The pathological diagnosis of the primary tumor specimen was Wilms' tumor with favorable histology.
  • Upon tumor recurrence, molecular detection of SYT-SSX2 fusion transcripts lead to the diagnosis of synovial sarcoma of the kidney.
  • To our knowledge, this is the first case of primary synovial sarcoma arising from a crossed ectopic kidney with fusion.
  • [MeSH-major] Kidney / abnormalities. Kidney Neoplasms / complications. Sarcoma, Synovial / complications

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377831.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


83. Misra S, Gordon JD, Fu AA, Glockner JF, Chade AR, Mandrekar J, Lerman L, Mukhopadhyay D: The porcine remnant kidney model of chronic renal insufficiency. J Surg Res; 2006 Oct;135(2):370-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The porcine remnant kidney model of chronic renal insufficiency.
  • BACKGROUND: The purpose of the present study was to develop and characterize a porcine model of chronic renal insufficiency created by renal artery embolization.
  • In the pilot group, the embolization procedure was optimized with respect to the size of polyvinyl acrylide (PVA) particles, coils, and amount of kidney embolized.
  • The animals were followed serially for 4 weeks after the embolization procedure to determine the renal function and hypertensive response.
  • RESULTS: The kidney function after the embolization was characterized by acute deterioration in renal function, followed by improvement, and "stable" chronic renal insufficiency with statistically significant elevation in creatinine and BUN being observed until day 42.
  • The remnant kidney developed fibrosis in the tublointerstitial compartment as it hypertrophied and increased its weight which remained significantly elevated after embolization.
  • CONCLUSIONS: A reproducible remnant kidney model of chronic renal insufficiency in pigs was developed.
  • In this model, stable renal insufficiency develops by 4 weeks that lasts until 12 weeks.
  • [MeSH-major] Disease Models, Animal. Kidney / pathology. Renal Insufficiency, Chronic / pathology
  • [MeSH-minor] Angiography. Animals. Blood Pressure. Blood Urea Nitrogen. Creatinine / metabolism. Male. Organ Size. Renal Artery Obstruction / surgery. Sus scrofa. Time Factors

  • MedlinePlus Health Information. consumer health - Chronic Kidney Disease.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16815448.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


84. Yang B, Sonawane ND, Zhao D, Somlo S, Verkman AS: Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol; 2008 Jul;19(7):1300-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease.
  • Cyst expansion in polycystic kidney disease (PKD) involves progressive fluid accumulation, which is believed to require chloride transport by the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
  • These compounds also inhibited cyst number and growth by >80% in an embryonic kidney cyst model involving 4-d organ culture of embryonic day 13.5 mouse kidneys in 8-Br-cAMP-containing medium.
  • Subcutaneous delivery of tetrazolo-CFTR(inh)-172 and Ph-GlyH-101 to neonatal, kidney-specific PKD1 knockout mice produced stable, therapeutic inhibitor concentrations of >3 microM in urine and kidney tissue.
  • Treatment of mice for up to 7 d remarkably slowed kidney enlargement and cyst expansion and preserved renal function.
  • These results implicate CFTR in renal cyst growth and suggest that CFTR inhibitors may hold therapeutic potential to reduce cyst growth in PKD.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. GLYCINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kidney Int. 1999 Apr;55(4):1187-97 [10200981.001]
  • [Cites] Am J Kidney Dis. 1998 Dec;32(6):976-83 [9856513.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32 [16203784.001]
  • [Cites] FASEB J. 2006 Jan;20(1):130-2 [16317066.001]
  • [Cites] J Nephrol. 2006 Jul-Aug;19(4):529-34 [17048214.001]
  • [Cites] Cell Tissue Res. 2006 Dec;326(3):671-85 [16767405.001]
  • [Cites] J Am Soc Nephrol. 2006 Dec;17(12):3424-37 [17108316.001]
  • [Cites] J Am Soc Nephrol. 2007 May;18(5):1399-407 [17429048.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1234-44 [17408659.001]
  • [Cites] Nat Genet. 2000 Jun;25(2):143-4 [10835625.001]
  • [Cites] Annu Rev Med. 2001;52:93-123 [11160770.001]
  • [Cites] J Am Soc Nephrol. 2002 Jul;13(7):1837-46 [12089379.001]
  • [Cites] J Am Soc Nephrol. 2002 Sep;13(9):2384-98 [12191984.001]
  • [Cites] J Clin Invest. 2002 Dec;110(11):1651-8 [12464670.001]
  • [Cites] Kidney Int. 2003 Jan;63(1):365-76 [12472805.001]
  • [Cites] N Engl J Med. 2004 Jan 8;350(2):151-64 [14711914.001]
  • [Cites] Mol Genet Metab. 2004 Feb;81(2):75-85 [14741187.001]
  • [Cites] FEBS Lett. 2004 Jan 30;558(1-3):52-6 [14759515.001]
  • [Cites] Nat Med. 2004 Apr;10(4):363-4 [14991049.001]
  • [Cites] J Gen Physiol. 2004 Aug;124(2):125-37 [15277574.001]
  • [Cites] Kidney Int. 2004 Nov;66(5):1926-38 [15496164.001]
  • [Cites] Scan Electron Microsc. 1986;(Pt 3):1135-50 [3798016.001]
  • [Cites] Scanning Microsc. 1988 Sep;2(3):1739-63 [3059485.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(15):6007-11 [2474825.001]
  • [Cites] Trans Assoc Am Physicians. 1989;102:158-62 [2561639.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):310-3 [8321258.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):332-42 [8321262.001]
  • [Cites] J Am Soc Nephrol. 1995 Oct;6(4):1230-41 [8589291.001]
  • [Cites] Hum Mol Genet. 2008 Jun 1;17(11):1505-16 [18263604.001]
  • [Cites] FASEB J. 1989 Dec;3(14):2629-32 [2480260.001]
  • [Cites] Kidney Int. 1996 Jul;50(1):208-18 [8807590.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10206-11 [8816777.001]
  • [Cites] Eur J Clin Invest. 1996 Jun;26(6):506-13 [8817166.001]
  • [Cites] Cell. 1996 Dec 13;87(6):979-87 [8978603.001]
  • [Cites] Biochem J. 1997 Feb 15;322 ( Pt 1):259-65 [9078271.001]
  • [Cites] Cell. 1998 Apr 17;93(2):177-88 [9568711.001]
  • [Cites] Physiol Rev. 1998 Oct;78(4):1165-91 [9790573.001]
  • [Cites] J Pharm Sci. 2005 Jan;94(1):134-43 [15761937.001]
  • (PMID = 18385427.001).
  • [ISSN] 1533-3450
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL73856; United States / NIDDK NIH HHS / DK / P50 DK057328; United States / NEI NIH HHS / EY / R01 EY013574; United States / NIBIB NIH HHS / EB / R01 EB000415; United States / NIDDK NIH HHS / DK / R01 DK054053; United States / NIDDK NIH HHS / DK / DK57328; United States / NIDDK NIH HHS / DK / R01 DK035124; United States / NHLBI NIH HHS / HL / R01 HL073856; United States / NIDDK NIH HHS / DK / P30 DK072517; United States / NIDDK NIH HHS / DK / DK54053; United States / NIDDK NIH HHS / DK / DK72517; United States / NHLBI NIH HHS / HL / R01 HL059198; United States / NEI NIH HHS / EY / EY13574; United States / NIDDK NIH HHS / DK / DK35124; United States / NIBIB NIH HHS / EB / EB00415; United States / NHLBI NIH HHS / HL / HL59198; United States / NIDDK NIH HHS / DK / R37 DK035124; United States / NIBIB NIH HHS / EB / R37 EB000415
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Cdh16 protein, mouse; 0 / TRPP Cation Channels; 0 / Thiazolidines; 0 / polycystic kidney disease 1 protein; 126880-72-6 / Cystic Fibrosis Transmembrane Conductance Regulator; 14379-80-7 / glycine hydrazide; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases; TE7660XO1C / Glycine
  • [Other-IDs] NLM/ PMC2440296
  •  go-up   go-down


85. Wang Y, Wang Z, Wang W, Ren H, Zhang W, Chen N: Analysis of factors associated with renal function in Chinese adults with congenital solitary kidney. Intern Med; 2010;49(20):2203-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of factors associated with renal function in Chinese adults with congenital solitary kidney.
  • BACKGROUND: Patients with congenital solitary kidney have an increased risk of developing hypertension, proteinuria and renal insufficiency.
  • However, the specific factors associated with the progression of renal function in adults with congenital solitary kidney remain still unclear.
  • The purpose of this study was to identify factors that are independently associated with renal function progression in patients with congenital solitary kidney.
  • METHODS: Sixty-five Chinese adults with congenital solitary kidney (48 patients with unilateral renal agenesis and 17 with severe unilateral renal dysplasia) were recruited into our study retrospectively.
  • RESULTS: Of sixty-five patients with congenital solitary kidney, the prevalence of hypertension, proteinuria and renal insufficiency was 36.9%, 35.4% and 38.5%, respectively.
  • While there was no statistically significant difference in prevalence of hypertension between patients with and without renal insufficiency, the prevalence of proteinuria in patients with renal insufficiency was significantly higher than in those without renal insufficiency (p<0.05).
  • Logistic regression analysis revealed that kidney length and proteinuria were independently associated with the progression of renal function (OR=0.20, 95%CI 0.05-0.79, and OR=8.30, 95%CI 2.30-29.96, respectively).
  • CONCLUSION: Hypertension, proteinuria or renal insufficiency was present in approximately one-third of adults with congenital solitary kidney.
  • Those with a kidney length of less than 120 mm or proteinuria had a much higher risk of renal insufficiency.
  • [MeSH-major] Hypertension, Renal / etiology. Kidney / abnormalities. Kidney Failure, Chronic / etiology. Proteinuria / etiology

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20962438.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 268B43MJ25 / Uric Acid; AYI8EX34EU / Creatinine
  •  go-up   go-down


86. Newsome BB, Warnock DG, Kiefe CI, Weissman NW, Houston TK, Centor RM, Person SD, McClellan WM, Allison JJ: Delay in time to receipt of thrombolytic medication among Medicare patients with kidney disease. Am J Kidney Dis; 2005 Oct;46(4):595-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delay in time to receipt of thrombolytic medication among Medicare patients with kidney disease.
  • BACKGROUND: Patients with kidney disease and acute myocardial infarction (AMI) receive standard therapy, including thrombolytic medication, less frequently than patients with normal kidney function.
  • Our goal is to identify potential differences in thrombolytic medication delays and thrombolytic-associated bleeding events by severity of kidney disease.
  • Average time to thrombolytic therapy was longer in patients with worse kidney function.
  • Adjusted hazard ratios for minutes to thrombolytic therapy were 0.83 (95% confidence interval [CI], 0.79 to 0.87) for patients with a serum creatinine level of 1.6 to 2.0 mg/dL (141 to 177 micromol/L) and 0.58 (95% CI, 0.53 to 0.63) for patients with a creatinine level greater than 2.0 mg/dL (>177 micromol/L) or on dialysis therapy compared with those with normal kidney function.
  • Odds ratios for bleeding events in patients administered thrombolytics versus those who were not decreased with worse kidney function: adjusted odds ratios, 2.28 (95% CI, 2.16 to 2.42) in patients with normal kidney function and 1.84 (95% CI, 1.09 to 3.10) in dialysis patients.
  • CONCLUSION: Patients with worse kidney function experienced treatment delays, but were not at greater risk for thrombolysis-associated excess bleeding events.
  • [MeSH-major] Fibrinolytic Agents / administration & dosage. Kidney Diseases / complications. Medicare / statistics & numerical data. Myocardial Infarction / drug therapy. Thrombolytic Therapy / statistics & numerical data

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Medicare.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16183413.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / T32 HS013852; United States / NHLBI NIH HHS / HL / R01 HL70786
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiovascular Agents; 0 / Fibrinolytic Agents; AYI8EX34EU / Creatinine
  •  go-up   go-down


87. Mazaris EM, Warrens AN, Papalois VE: Ethical issues in live donor kidney transplant: views of medical and nursing staff. Exp Clin Transplant; 2009 Mar;7(1):1-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethical issues in live donor kidney transplant: views of medical and nursing staff.
  • OBJECTIVES: The ongoing development of live donor kidney transplant has generated many ethical dilemmas.
  • MATERIALS AND METHODS: An anonymous and confidential questionnaire was sent to 236 members of the medical and nursing staff of the West London Renal and Transplant Centre, to assess their views on the ethics of the current practice of live donor kidney transplant.
  • Respondents considered live donor kidney transplant ethically acceptable between blood relatives (100%), nonblood relatives and friends (92.6%), and strangers (47.2%).
  • Most respondents were willing to donate a kidney to a blood relative (92.6%) or a nonblood relative or friend (81.5%), and 12.0% were willing to donate to a stranger.
  • Considering themselves as potential recipients if they had end-stage renal disease, most would accept a kidney from a blood relative (91.7%) or nonblood relative or friend (85.2%),while 44.5% would accept a kidney from a stranger.
  • CONCLUSIONS: Live related and unrelated kidney donation are considered ethically acceptable procedures, and nondirected donation is gaining support among transplant professionals.
  • [MeSH-major] Attitude of Health Personnel. Directed Tissue Donation / ethics. Health Knowledge, Attitudes, Practice. Kidney Transplantation / ethics. Living Donors / ethics. Tissue and Organ Procurement / ethics

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19364304.001).
  • [ISSN] 1304-0855
  • [Journal-full-title] Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  • [ISO-abbreviation] Exp Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


88. Mozer P, Leroy A, Payan Y, Troccaz J, Chartier-Kastler E, Richard F: Computer-assisted access to the kidney. Int J Med Robot; 2005 Dec;1(4):58-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-assisted access to the kidney.
  • OBJECTIVES: The aim of this paper is to introduce the principles of computer-assisted access to the kidney.
  • MATERIAL AND METHODS: Both CT and US images of informed normal volunteer were obtained to perform calculation on the accuracy of registration and punctures were carried out on a kidney phantom to measure the precision of the whole of the system.
  • RESULTS: We carried out millimetric registrations on real data and guidance experiments on a kidney phantom showed encouraging results of 4.7 mm between planned and reached targets.
  • [MeSH-major] Kidney / surgery. Surgery, Computer-Assisted

  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 John Wiley & Sons, Ltd.
  • (PMID = 17518406.001).
  • [ISSN] 1478-596X
  • [Journal-full-title] The international journal of medical robotics + computer assisted surgery : MRCAS
  • [ISO-abbreviation] Int J Med Robot
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Geel A, Zuidema W, van Gelder T, van Doornum G, Weimar W: Successful vaccination against varicella zoster virus prior to kidney transplantation. Transplant Proc; 2005 Mar;37(2):952-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful vaccination against varicella zoster virus prior to kidney transplantation.
  • BACKGROUND: In recent years we have observed a number of severe complications of primary varicella-zoster virus (VZV) infections after adult kidney transplantation.
  • We questioned how many patients on the waiting list for kidney transplantation had not been protected against VZV and whether patients with renal insufficiency would be able to develop a specific immune response upon VZV vaccination.
  • METHODS: We examined the VZV antibody titer of 280 patients on the kidney transplant waiting list.
  • Seronegative kidney transplant candidates were vaccinated twice with a live attenuated varicella vaccine at an interval of 6 weeks.
  • [MeSH-major] Antibodies, Viral / blood. Chickenpox / immunology. Chickenpox Vaccine / therapeutic use. Kidney Transplantation / immunology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chickenpox.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848586.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Chickenpox Vaccine
  •  go-up   go-down


90. Bader AA, Tamussino KF, Winter R: Ectopic (pelvic) kidney mimicking bulky lymph nodes at pelvic lymphadenectomy. Gynecol Oncol; 2005 Mar;96(3):873-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic (pelvic) kidney mimicking bulky lymph nodes at pelvic lymphadenectomy.
  • BACKGROUND: Ectopic (pelvic) kidney is the most common congenital renal anomaly with an incidence of 1 in 500 to 1 in 2000.
  • A pelvic kidney can be encountered at pelvic or paraaortic lymphadenectomy.
  • CASE REPORTS: In two patients undergoing pelvic lymphadenectomy, lobulated tumors near the pelvic brim were initially interpreted as bulky lymph node conglomerates.
  • Further dissection showed the ureter to originate from the masses, leading to a diagnosis of pelvic kidney.
  • CONCLUSION: Pelvic kidneys mistaken for bulky lymph nodes are a potential intraoperative pitfall in patients with gynecologic malignancies.
  • Keys to recognition include an index of suspicion, identifying the course of the ureter and origin of the renal vessels, and confirming absence of a kidney at the normal location.
  • [MeSH-major] Genital Neoplasms, Female / surgery. Kidney / abnormalities. Lymph Nodes / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721442.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Mekeel KL, Mazur MJ, Reddy KS, Mulligan DC, Heilman RL, Chakkera HA, Andrews PE, Moss AA: Diffuse parenchymal urine leak after kidney transplantation following degloving injury during donor nephrectomy. Am J Transplant; 2007 Aug;7(8):2039-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse parenchymal urine leak after kidney transplantation following degloving injury during donor nephrectomy.
  • Laparoscopic donor nephrectomy can result in trauma to the kidney which may affect recipient graft function.
  • In this case, the kidney sustained a complete degloving of the capsule during extraction.
  • The kidney was transplanted and had immediate, good renal function, but postoperative course was complicated by a large urinoma that drained through the wound.
  • Exploration was negative for a defined urine leak, but the surface of the denuded kidney was leaking a significant amount of unconcentrated urine.
  • The patient was successfully treated with tissue glue treatment to the kidney surface and peritoneal window.
  • [MeSH-major] Intraoperative Complications. Kidney / injuries. Kidney Transplantation / adverse effects. Laparoscopy / adverse effects. Nephrectomy / adverse effects. Tissue Donors. Tissue and Organ Procurement / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578504.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


92. Murugesan M, Courtauld E, Fisher C, Nathan S: Renal capsular PEComa--a rare cause of surgically correctable renal hypertension. Int Urol Nephrol; 2007;39(3):705-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal capsular PEComa--a rare cause of surgically correctable renal hypertension.
  • This indicated a complex cystic lesion, measuring 2.4 x 5 x 10 cms , arising from the right kidney.
  • The mass was reported as a Perivascular Epitheloid Cell (PEC) lesion (PEComa) arising from the renal capsule.
  • Perivascular Epitheloid Cell tumor (PEComa), a recently defined tumor, is extremely rare.
  • PEComa's are usually benign, but cases have been reported in the literature which has an unfavourable outcome with metastatic dissemination.
  • We report this case because of its rarity and also Renal Capsular PEComa should be considered as a rare cause of renal hypertension, which can be surgically cured.
  • [MeSH-major] Epithelioid Cells / pathology. Hypertension, Renal / etiology. Kidney Neoplasms / complications. Neoplasms, Connective Tissue / complications

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2006 Jan;48(1):75-82 [16359539.001]
  • [Cites] Pathology. 1991 Jul;23(3):185-8 [1664078.001]
  • [Cites] Eur J Cancer. 1993;29A(13):1903-7 [8260252.001]
  • (PMID = 17318350.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


93. Krajisnik T, Olauson H, Mirza MA, Hellman P, Akerström G, Westin G, Larsson TE, Björklund P: Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int; 2010 Nov;78(10):1024-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients.
  • However, patients with chronic kidney disease (CKD) develop secondary hyperparathyroidism despite high levels of serum FGF23, indicating a parathyroid FGF23 'resistance'.
  • Here we analyzed the expression of the FGF23 receptors Klotho and FGF receptor 1 (FGFR1) in 88 hyperplastic parathyroid glands from 31 patients with CKD (including 21 renal allograft recipients), and their regulation in isolated bovine and human hyperplastic parathyroid cells.
  • Thus parathyroid Klotho and FGFR1 decrease with declining renal function, possibly because of alterations in mineral metabolism related to the failing kidney.
  • [MeSH-major] Glucuronidase / metabolism. Hyperparathyroidism / metabolism. Kidney / physiopathology. Kidney Diseases / metabolism. Kidney Transplantation / physiology. Parathyroid Glands / metabolism. Receptors, Fibroblast Growth Factor / metabolism

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Kidney Int. 2010 Nov;78(10):953-5 [21030971.001]
  • (PMID = 20686451.001).
  • [ISSN] 1523-1755
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Minerals; 0 / Parathyroid Hormone; 0 / Receptors, Calcitriol; 0 / Receptors, Fibroblast Growth Factor; 0 / fibroblast growth factor 23; 62031-54-3 / Fibroblast Growth Factors; EC 3.2.1.31 / Glucuronidase; EC 3.2.1.31 / klotho protein
  •  go-up   go-down


94. Bouman CS, Oudemans-van Straaten HM: Timing of renal replacement therapy in critically ill patients with acute kidney injury. Curr Opin Crit Care; 2007 Dec;13(6):656-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timing of renal replacement therapy in critically ill patients with acute kidney injury.
  • PURPOSE OF REVIEW: Timing of renal replacement therapy in critically ill patients with acute kidney injury is highly subjective, and may influence outcome.
  • We discuss renal and nonrenal criteria for timing considering the recent literature.
  • All but one randomized controlled trial indicated better outcome with early renal replacement therapy but had poor methodological quality.
  • SUMMARY: In the absence of large randomized controlled trials we can make no firm recommendations for timing of renal replacement therapy in acute kidney injury.
  • Since rapid recovery of renal function is unlikely when other organ failure persists and the consequences of acute kidney injury may be more severe in critically ill patients, we suggest other organ failure is also considered.
  • Patients with acute kidney injury, persisting shock and poorly recovering functions of other organs may benefit from early therapy.
  • For future studies, we recommend describing renal replacement therapy timing according to the 'RIFLE' classification, as modified by the Acute Kidney Injury Network, and quantifying the severity of other organ failure.
  • Biomarkers may refine acute kidney injury and timing definitions in the future.
  • [MeSH-major] Acute Kidney Injury / therapy. Critical Illness. Kidney / injuries. Renal Replacement Therapy / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975386.001).
  • [ISSN] 1070-5295
  • [Journal-full-title] Current opinion in critical care
  • [ISO-abbreviation] Curr Opin Crit Care
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 51
  •  go-up   go-down


95. Sudarshan S, Linehan WM: Genetic basis of cancer of the kidney. Semin Oncol; 2006 Oct;33(5):544-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic basis of cancer of the kidney.
  • Kidney cancer is not a single disease.
  • It is made up of a number of different types of cancer that occur in the kidney, each with a different histologic type, having a different clinical course, responding differently to therapy and caused by a different gene.
  • The identification of families with a predisposition to the development of renal neoplasms, including von Hippel-Lindau (VHL), hereditary papillary renal carcinoma (HPRC), Birt-Hogg-Dubé (BHD), and hereditary leiomyomatosis and renal cell cancer (HLRCC), has made possible the identification of the different genes for these cancers.
  • The elucidation of molecular pathogenesis in these familial forms of kidney cancer should provide the opportunity to determine successful approaches for novel therapeutic agents.
  • [MeSH-major] Carcinoma, Papillary / genetics. Carcinoma, Renal Cell / genetics. Genetic Predisposition to Disease. Kidney Neoplasms / genetics. von Hippel-Lindau Disease / genetics

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17045083.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 87
  •  go-up   go-down


96. Kalb B, Martin DR, Salman K, Sharma P, Votaw J, Larsen C: Kidney transplantation: structural and functional evaluation using MR Nephro-Urography. J Magn Reson Imaging; 2008 Oct;28(4):805-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney transplantation: structural and functional evaluation using MR Nephro-Urography.
  • End-stage-renal disease (ESRD) is a major health issue in the United States, and the Medicare costs of ESRD totaled nearly USD 21 billion in 2005.
  • Renal transplantation has emerged as the treatment of choice in this patient population, providing improved quality of life and lower healthcare costs compared with other treatment options.
  • Imaging evaluation of a graft kidney plays a critical role in the postoperative care of the renal transplant patient.
  • In the past, diagnostic evaluation of the transplant kidney has depended upon a combination of ultrasonography, computed tomography, MRI, and biopsy, used in conjunction with the patient's clinical presentation.
  • However, new and developing advances in MR technology has lead to the development of MR Nephro-Urography (MRNU), which provides both anatomic and functional evaluation of the kidney in a single examination.
  • It is expected that the increasing use of MRNU will have a significant impact on the management of renal transplant patients.
  • This review describes MRNU methodology, examines known posttransplant complications, and highlights the utility of MRNU as a comprehensive imaging examination to diagnose both surgical and medical complications of the transplant kidney.
  • [MeSH-major] Kidney / blood supply. Kidney Failure, Chronic / surgery. Kidney Transplantation. Magnetic Resonance Imaging / methods. Postoperative Complications / diagnosis
  • [MeSH-minor] Graft Rejection. Graft Survival. Humans. Recovery of Function. Renal Dialysis


97. Olson GE, Winfrey VP, Hill KE, Burk RF: Megalin mediates selenoprotein P uptake by kidney proximal tubule epithelial cells. J Biol Chem; 2008 Mar 14;283(11):6854-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Megalin mediates selenoprotein P uptake by kidney proximal tubule epithelial cells.
  • Selenoprotein P (Sepp1) contains most of the selenium in blood plasma, and it is utilized by the kidney, brain, and testis as a selenium source for selenoprotein synthesis.
  • We recently demonstrated that apolipoprotein E receptor-2 (ApoER2) is required for Sepp1 uptake by the testis and that deletion of ApoER2 reduces testis and brain, but not kidney, selenium levels.
  • This study examined the kidney Sepp1 uptake pathway.
  • Tissue ligand binding assays using cryosections of Sepp1-/- kidneys revealed that the proximal tubule epithelium contained Sepp1-binding sites that were blocked by the receptor-associated protein, RAP, an inhibitor of lipoprotein receptor-ligand interactions.
  • Ligand blotting assays of kidney membrane preparations fractionated by SDS-PAGE revealed that Sepp1 binds megalin, a lipoprotein receptor localized to the proximal tubule epithelium.
  • Immunolocalization analyses confirmed the in vivo co-localization of Sepp1 and megalin in wild type kidneys and demonstrated the absence of proximal tubule Sepp1 uptake in megalin null mice.
  • These results demonstrate that kidney selenium homeostasis is mediated by a megalin-dependent Sepp1 uptake pathway in the proximal tubule.
  • [MeSH-major] Epithelial Cells / metabolism. Gene Expression Regulation. Kidney Tubules / cytology. Low Density Lipoprotein Receptor-Related Protein-2 / physiology. Selenoprotein P / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18174160.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES02497; United States / NICHD NIH HHS / HD / HD044863
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LDL-Receptor Related Proteins; 0 / Low Density Lipoprotein Receptor-Related Protein-2; 0 / Receptors, Lipoprotein; 0 / Selenoprotein P; 0 / low density lipoprotein receptor-related protein 8
  •  go-up   go-down


98. Mabrut JY, Boulez J, Peix JL, Gigot JF, Gouillat C, de La Roche E, Ducerf C, Baulieux J: Laparoscopic pancreatic resection: a preliminary experience of 15 patients. Hepatogastroenterology; 2005 Jan-Feb;52(61):230-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODOLOGY: 15 consecutive patients suffering from benign cystic pancreatic (n=6), neuroendocrine tumors (n=8) or pancreatic metastasis from renal carcinoma (n=1) undergoing laparoscopic pancreatic resection were retrospectively collected from 5 academic hospitals.
  • RESULTS: Laparoscopic procedure was completed in 10 patients, including 7 distal pancreatectomies (with 5 spleen preservation), 2 tumor enucleations and 1 partial cystic resection.
  • CONCLUSIONS: Laparoscopic pancreatic resection is feasible for distal pancreatic tumors.
  • [MeSH-major] Cystadenoma / surgery. Laparoscopy. Neuroendocrine Tumors / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kidney Neoplasms / pathology. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783037.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


99. Patel TY, Hovsepian DM, Duncan JR: Measurement of blood flow before and after embolization with use of fluorescent microspheres in an animal model. J Vasc Interv Radiol; 2006 Jan;17(1):103-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Catheter-directed embolization has become a widespread technique for the treatment of benign and malignant neoplasms.
  • The mechanism whereby embolization leads to selective atrophy of these neoplasms is largely speculative.
  • As a potential model for the large regional perfusion differences between normal and neoplastic tissues, renal perfusion was studied before and after catheter-directed embolization.
  • The working hypothesis was that embolization would create measurable changes in blood flow in the renal cortex and medulla.
  • MATERIALS AND METHODS: Microspheres (l0 microm in diameter) containing a series of different fluorophores were injected into the arterial system before and after the renal arteries were embolized with a series of larger (100-300 microm) particulate embolic agents.
  • The distribution of the microspheres in the renal cortex, renal medulla, and liver was analyzed by fluorescence microscopy as well as by extraction of the fluorophores.
  • Before embolization, the renal cortex received approximately three times more flow than the medulla.
  • After embolization, perfusion of the renal cortex and medulla decreased in parallel.
  • The fact that parallel decreases in flow were found in the renal cortex and medulla indicates that the distribution of each embolic agent was flow-directed.
  • These results might provide insight into the mechanism of tumor atrophy after uterine artery embolization or hepatic chemoembolization.
  • [MeSH-major] Embolization, Therapeutic. Kidney Neoplasms / therapy. Microspheres. Renal Circulation
  • [MeSH-minor] Animals. Female. Fluorescent Dyes / administration & dosage. Kidney Cortex / blood supply. Kidney Medulla / blood supply. Microscopy, Fluorescence. Models, Animal. Rabbits. Radiography, Interventional. Renal Artery